<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1709245919
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2006
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SETRAL 50MG F.C. TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SERTRALINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        54.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1055]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Dallah Health Care Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AB06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SETRAL contains the active substance Sertraline.<br />Sertraline is one of a group of medicines called<br />Selective Serotonin Re-uptake Inhibitors (SSRIs);<br />these medicines are used to treat depression and/or<br />anxiety disorders.<br />SETRAL can be used to treat:<br />□ Depression and prevention of recurrence of<br />depression (in adults) □ Social anxiety disorder (in<br />adults) □ Post traumatic stress disorder (PTSD) (in<br />adults) □ Panic disorder (in adults)<br />□ Obsessive compulsive disorder (OCD) (in adults and<br />children and adolescents aged 6-17 years old).<br />- Depression is a clinical illness with symptoms like<br />feeling sad, unable to sleep properly or to enjoy life as<br />you used to.<br />- OCD and Panic disorders are illnesses linked to<br />anxiety with symptoms like being constantly troubled<br />by persistent ideas (obsessions) that make you carry<br />out repetitive rituals (compulsions).<br />- PTSD is a condition that can occur after a very<br />emotionally traumatic experience, and has some<br />symptoms that are similar to depression and anxiety.<br />Social anxiety disorder (social phobia) is an illness<br />linked to anxiety. It is characterised by feelings of<br />intense anxiety or distress in social situations (for<br />example: talking to strangers, speaking in front of<br />groups of people, eating or drinking in front of others<br />or worrying that you might behave in an embarrassing<br />manner).<br />Your doctor has decided that this medicine is suitable<br />for treating your illness.<br />You should ask your doctor if you are unsure why you<br />have been given SETRAL.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take SETRAL:<br />□ If you are allergic to Sertraline or any of the other<br />ingredients of SETRAL (listed in section 6).<br />□ If you are taking or have taken medicines called<br />monoamine oxidase inhibitors (MAOIs such as<br />selegiline, moclobemide) or MAOI like drugs (such as<br />linezolid). If you stop treatment with Sertraline, you<br />must wait until at least one week before you start<br />treatment with a MAOI. After stopping treatment with<br />a MAOI, you must wait at least 2 weeks before you<br />can start treatment with Sertraline.<br />□ If you are taking another medicine called Pimozide<br />(a medicine for mental disorders such as psychosis).<br />Take special care with SETRAL:<br />Talk to your doctor or pharmacist before taking<br />SETRAL.<br />Medicines are not always suitable for everyone. Tell<br />your doctor before you take SETRAL, if you suffer<br />from or have suffered in the past from any of the<br />following conditions:<br />□ If you have epilepsy (fit) or a history of seizures. If<br />you have a fit (seizure), contact your doctor<br />immediately.<br />□ If you have suffered from manic depressive illness<br />(bipolar disorder) or schizophrenia. If you have a<br />manic episode, contact your doctor immediately.<br />□ If you have or have previously had thoughts of<br />harming or killing yourself (see below-Thoughts of<br />suicide and worsening of your depression or anxiety<br />disorder).<br />□ If you have Serotonin Syndrome. In rare cases this<br />syndrome may occur when you are taking certain<br />medicines at the same time as Sertraline. (For<br />symptoms, see section 4. Possible Side Effects). Your<br />doctor will have told you whether you have suffered<br />from this in the past.<br />□ If you have low sodium level in your blood, since this<br />can occur as a result of treatment with SETRAL. You<br />should also tell your doctor if you are taking certain<br />medicines for hypertension, since these medicines<br />may also alter the sodium level in your blood.<br />□ If you are elderly as you may be more at risk of<br />having low sodium level in your blood (see above).<br />□ If you have Liver disease; your doctor may decide<br />that you should have a lower dose of SETRAL.<br />□ If you have Diabetes; your blood glucose levels may<br />be altered due to SETRAL and your diabetes<br />medicines may need to be adjusted.<br />□ If you have suffered from bleeding disorders or have<br />been taking medicines which thin the blood (e.g.<br />acetylsalicyclic acid (aspirin), or warfarin) or may<br />increase the risk of bleeding.<br />□ If you are a child or adolescent under 18 years old.<br />SETRAL should only be used to treat children and<br />adolescents aged 6-17 years old, suffering from<br />obsessive compulsive disorder (OCD). If you are being<br />treated for this disorder, your doctor will want to<br />monitor you closely (see below Use in children and<br />adolescents).<br />□ If you are having electro-convulsive therapy (ECT).<br />□ If you have eye problems, such as certain kinds of<br />glaucoma (increased pressure in the eye).<br />□ If you have been told that you have an abnormality<br />of your heart tracing after an electrocardiogram (ECG)<br />known as prolonged QT interval.<br />□ If you have heart disease, low potassium levels or<br />low magnesium levels, family history of QT<br />prolongation, low heart rate and concomitant use of<br />medications which prolong QT interval.<br />Restlessness/Akathisia: The use of Sertraline has<br />been linked to a distressing restlessness and need to<br />move, often being unable to sit or stand still<br />(akathisia). This is most likely to occur during the first<br />few weeks of treatment. Increasing the dose may be<br />harmful so if you develop such symptoms you should<br />talk to your doctor.<br />Withdrawal reactions: Side effects relating to stopping<br />treatment (withdrawal reactions) are common,<br />particularly if the treatment is stopped suddenly (see<br />section 3 If you stop taking SETRAL and section 4<br />Possible side effects). The risk of withdrawal<br />symptoms depends on the length of treatment, dosage<br />and the rate at which the dose is reduced. Generally,<br />such symptoms are mild to moderate. However, they<br />can be serious in some patients. They normally occur<br />within the first few days after stopping treatment. In<br />general, such symptoms disappear on their own and<br />wear off within 2 weeks. In some patients they may<br />last longer (2-3 months or more). When stopping<br />treatment with Sertraline it is recommended to reduce<br />the dose gradually over a period of several weeks or<br />months and you should always discuss the best way<br />of stopping treatment with your doctor.<br />Thoughts of suicide and worsening of your depression<br />or anxiety disorder: If you are depressed and/or have<br />anxiety disorders you can sometimes have thoughts of<br />harming or killing yourself. These may be increased<br />when first starting antidepressants, since these<br />medicines all take time to work, usually about two<br />weeks but sometimes longer.<br />You may be more likely to think like this:<br />□ If you have previously had thoughts about killing or<br />harming yourself.<br />□ If you are a young adult. Information from clinical<br />trials has shown an increased risk of suicidal<br />behaviour in adults aged less than 25 years with<br />psychiatric conditions who were treated with an<br />antidepressant.<br />If you have thoughts of harming or killing yourself at<br />any time, contact your doctor or go to a hospital<br />straight away.<br />You may find it helpful to tell a relative or close friend<br />that you are depressed or have an anxiety disorder<br />and ask them to read this leaflet. You might ask them<br />to tell you if they think your depression or anxiety is<br />getting worse, or if they are worried about changes in<br />your behaviour.<br />Sexual problems:<br />Medicines like SETRAL (so called SSRIs) may cause<br />symptoms of sexual dysfunction (see section 4). In<br />some cases, these symptoms have continued after<br />stopping treatment.<br />Children and adolescents: Sertraline should not<br />usually be used in children and adolescents less than<br />18 years old, except for patients with Obsessive<br />Compulsive Disorder (OCD). Patients under 18 have<br />an increased risk of undesirable effects, such as<br />suicide attempt, thoughts of harming or killing<br />themselves (suicidal thoughts) and hostility (mainly<br />aggressiveness, oppositional behaviour and anger)<br />when they are treated with this class of medicines.<br />Nevertheless, it is possible that your doctor decides to<br />prescribe SETRAL to a patient under 18 if it is in the<br />patient&#39;s interest. If your doctor has prescribed<br />SETRAL to you and you are less than 18 years old<br />and you want to discuss this, please contact him/her.<br />Furthermore, if any of the symptoms listed above<br />appear or worsen while you are taking SETRAL, you<br />should inform your doctor. Also, the long-term safety of<br />SETRAL in regard to growth, maturation and learning<br />(cognitive) and behavioural development in this age<br />group has not yet been demonstrated.<br />- SSRIs/SNRIs may increase the risk of postpartum<br />hemorrhage.<br />Taking other medicines with SETRAL:<br />Tell your doctor or pharmacist if you are taking or<br />have recently taken any other medicines.<br />Some medicines can affect the way SETRAL works,<br />or SETRAL itself can reduce the effectiveness of<br />other medicines taken at the same time.<br />Taking SETRAL together with the following medicines<br />may cause serious side effects:<br />□ Medicines called monoamine oxidase inhibitors<br />(MAOIs), like moclobemide (to treat depression) and<br />selegiline (to treat Parkinson&rsquo;s disease), the antibiotic<br />linezolid and methylene blue (to treat high levels of<br />methaemoglobin in the blood). Do not use SETRAL<br />together with these medicines.<br />□ Medicines to treat mental disorders such as<br />psychosis (pimozide). Do not use SETRAL together<br />with pimozide.<br />Talk to your doctor if you are taking the following<br />medicine:<br />□ Medicines containing amphetamines (used to treat<br />attention deficit hyperactivity disorder (ADHD),<br />narcolepsy, and obesity). □ Herbal medicine<br />containing St. John&rsquo;s Wort (Hypericum perforatum).<br />The effects of St. John&rsquo;s Wort may last for 1-2 weeks<br />□ Products containing the amino acid tryptophan<br />□ Medicines to treat severe pain (e.g. tramadol)<br />□ Medicines used in anaesthesia or to treat chronic<br />pain (eg.fentanyl, mivacurium and suxamethonium)<br />□ Medicines to treat migraines (e.g. sumatriptan)<br />□ Blood thinning medicine (warfarin) □ Medicines to<br />treat pain/arthritis (Non steroidal anti-inflammatory<br />drug (NSAID) such as ibuprofen, acetylsalicylic acid<br />(aspirin)) □ Sedatives (diazepam) □ Diuretics (also<br />called &lsquo;water&rsquo; tablets) □ Medicines to treat epilepsy<br />(phenytoin, phenobarbital, carbamazepine)<br />□ Medicines to treat diabetes (tolbutamide)<br />□ Medicines to treat excessive stomach acid, ulcers<br />and heartburn (cimetidine,omeprazole, lanzoprazole,<br />pantoprazole, rabeprazole) □ Medicines to treat<br />mania and depression (lithium) □ Other medicines to<br />treat depression (such as amitriptyline, nortriptyline,<br />nefazodone, fluoxetine, fluvoxamine) □ Medicines to<br />treat schizophrenia and other mental disorders (such<br />as perphenazine, levomepromazine and olanzapine)<br />□ Medicines used to treat high blood pressure, chest<br />pain or regulate the rate and rhythm of the heart (such<br />as verapamil, diltiazem,flecainide, propafenone)<br />□ Medicines used to treat bacterial infections (such as<br />rifampicin, clarithromycin, telithromycin, erythromycin)<br />□ Medicines used to treat fungal infections (such as<br />ketoconazole, itraconazole, posaconazole,<br />voriconazole, fluconazole) □ Medicines used to treat<br />HIV/AIDS and Hepatitis C (protease inhibitors such as<br />ritonavir, telaprevir) □ Medicines used to prevent<br />nausea and vomiting after an operation or<br />chemotherapy (aprepitant) □ Medicines known to<br />increase the risk of changes in the electrical activity of<br />the heart (e.g. some antipsychotics and antibiotics).<br />Taking SETRAL with food, drink and alcohol:<br />□ SETRAL tablets can be taken with or without food<br />□ Alcohol should be avoided whilst taking SETRAL<br />□ Sertraline should not be taken in combination with<br />grapefruit juice, as this may increase the level of<br />Sertraline in your body.<br />Pregnancy, breastfeeding and fertility:<br />If you are pregnant or breast-feeding, think you may<br />be pregnant or are planning to have a baby, ask your<br />doctor or pharmacist for advice before taking this<br />medicine.<br />The safety of Sertraline has not been fully established<br />in pregnant women. Sertraline will only be given to<br />you when pregnant if your doctor considers that the<br />benefit for you is greater than any possible risk to the<br />developing baby.<br />Make sure your midwife and/or doctor know you are<br />on SETRAL. When taken during pregnancy,<br />particularly in the last 3 months of pregnancy,<br />medicines like SETRAL may increase the risk of a<br />serious condition in babies, called persistent<br />pulmonary hypertension of the newborn (PPHN),<br />making the baby breathe faster and appear bluish.<br />These symptoms usually begin during the first 24<br />hours after the baby is born. If this happens to your<br />baby you should contact your midwife and/or doctor<br />immediately.<br />Your newborn baby might also have other conditions,<br />which usually begin during the first 24 hours after<br />birth. Symptoms include:<br />□ Trouble with breathing □ A blueish skin or being too<br />hot or cold □ Blue lips □ Vomiting or not feeding<br />properly □ Being very tired, not able to sleep or<br />crying a lot □ Stiff or floppy muscles □ Tremors,<br />jitters or fits □ Increased reflex reactions<br />□ Irritability, □ Low blood sugar<br />If your baby has any of these symptoms when it is<br />born, or you are concerned about your baby&rsquo;s health,<br />contact your doctor or midwife who will be able to<br />advise you.<br />There is evidence that Sertraline passes into human<br />breast milk. Sertraline should only be used in women<br />during breast-feeding, if your doctor considers that the<br />benefit exceeds any possible risk to the baby.<br />Some medicines like sertraline may reduce the quality<br />of sperm in animal studies. Theoretically, this could<br />affect fertility, but impact on human fertility has not<br />been observed as yet.<br />Observational data indicate an increases risk (less<br />than 2- fold) of post partum hemorrhage following<br />SSRI/ SNRI exposure within the month prior to birth.<br />Driving and using machines:<br />Psychotropic drugs such as Sertraline may influence<br />your ability to drive or use machines. You should<br />therefore not drive or operate machinery, until you<br />know how this medication affects your ability to<br />perform these activities.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take SETRAL exactly as your doctor has told<br />you. Check with your doctor or pharmacist if you are<br />not sure.<br />The recommended dose is:<br />Adults:<br />□ Depression and Obssessive Compulsive Disorder:<br />For depression and OCD, the usual effective dose is<br />50 mg/day. The daily dose may be increased in 50 mg<br />increments and at intervals of at least one week over<br />a period of weeks. The maximum recommended dose<br />is 200 mg/day.<br />□ Panic disorder, Social anxiety disorder and Post<br />Traumatic Stress Disorder: For panic disorder, social<br />anxiety disorder and post traumatic stress disorder,<br />treatment should be started at 25 mg/day, and<br />increased to 50 mg/day after one week. The daily<br />dose then may be increased in 50 mg increments<br />over a period of weeks. The maximum recommended<br />dose is 200 mg/day.<br />Use in children and adolescents:<br />SETRAL must only be used to treat children and<br />adolescents suffering from OCD (Obsessive<br />Compulsive Disorder) aged 6-17 years old.<br />Obsessive Compulsive Disorder:<br />□ Children aged 6 to 12: the recommended starting<br />dose is 25 mg daily. After one week, your doctor may<br />increase this to 50 mg daily. The maximum dose is<br />200 mg daily.<br />□ Adolescents aged 13 to 17: the recommended<br />starting dose is 50 mg daily. The maximum dose is<br />200 mg daily.<br />If you have liver or kidney problems, please tell your<br />doctor and follow the doctor&rsquo;s instructions.<br />Method of administration:<br />□ SETRAL tablets may be taken with or without food.<br />□ Take your medication once daily either in the<br />morning or evening.<br />Your doctor will advise you on how long to take this<br />medication. This will depend on the nature of your<br />illness and how well you are responding to the<br />treatment. It may take several weeks before your<br />symptoms begin to improve. Treatment of depression<br />should usually continue for 6 months after<br />improvement.<br />If you take more SETRAL than you should: If you<br />accidentally take too much SETRAL contact your<br />doctor at once or go to the nearest hospital casualty<br />department. Always take the labelled medicine<br />package with you, whether there is any medication<br />left or not.<br />Symptoms of overdose may include drowsiness,<br />nausea and vomiting, rapid heart rate, shaking,<br />agitation, dizziness and in rare cases<br />unconsciousness.<br />If you forget to take SETRAL: Do not take a double<br />dose to make up for a forgotten dose. If you forget to<br />take a dose, do not take the missed dose. Just take<br />the next dose at the right time.<br />If you stop taking SETRAL: Do not stop taking<br />SETRAL unless your doctor tells you to. Your doctor<br />will want to gradually reduce your dose of SETRAL<br />over several weeks, before you finally stop taking this<br />medicine. If you suddenly stop taking this medicine<br />you may experience side effects such as dizziness,<br />numbness, sleep disturbances, agitation or anxiety,<br />headaches, feeling sick, being sick and shaking. If<br />you experience any of these side effects, or any other<br />side effects whilst stopping taking SETRAL, please<br />speak to your doctor.<br />If you have any questions on the use of this product,<br />ask your doctor or pharmacist</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, SETRAL can cause side effects,<br />although not everybody gets them.<br />Nausea is the most common side effect. The side<br />effects depend on the dose and often disappear or<br />lessen with continued treatment.<br />Tell your doctor immediately:<br />If you experience any of the following symptoms after<br />taking this medicine, these symptoms can be serious.<br />□ If you develop a severe skin rash that causes<br />blistering (erythema multiforme), (this can affect the<br />mouth and tongue). These may be signs of a<br />condition known as Stevens Johnson Syndrome, or<br />Toxic Epidermal Necrolysis (TEN). Your doctor will<br />stop your treatment in these cases.<br />□ Allergic reaction or allergy, which may include<br />symptoms such as an itchy skin rash, breathing<br />problems, wheezing, swollen eyelids, face or lips.<br />□ If you experience agitation, confusion, diarrhoea,<br />high temperature and blood pressure, excessive<br />sweating and rapid heartbeat. These are symptoms of<br />Serotonin Syndrome. In rare cases this syndrome may<br />occur when you are taking certain medicines at the<br />same time as Sertraline. Your doctor may wish to stop<br />your treatment.<br />□ If you develop yellow skin and eyes which may<br />mean liver damage.<br />□ If you experience depressive symptoms with ideas<br />of harming or killing yourself (suicidal thoughts).<br />□ If you start to get feelings of restlessness and are<br />not able to sit or stand still after you start to take<br />SETRAL. You should tell your doctor if you start to feel<br />restless.<br />□ If you have a fit (seizure).<br />□ If you have a manic episode (see section 2 &ldquo;Take<br />special care with SETRAL&rdquo;).<br />The following side effects were seen in clinical trials in<br />adults and after marketing.<br />Very common (may affect more than 1 in 10<br />people):<br />Insomnia, dizziness, sleepiness, headache, diarrhoea,<br />feeling sick, dry mouth, ejaculation failure, fatigue.<br />Common (may affect up to 1 in 10 people):<br />□ Chest cold, sore throat, runny nose □ Decreased<br />appetite, increased appetite<br />□ Anxiety, depression, agitation, decreased sexual<br />interest, nervousness, feeling strange, nightmare,<br />teeth grinding<br />□ Shaking, muscular movement problems (such as<br />moving a lot, tense muscles, difficulty walking and<br />stiffness, spasms and involuntary movements of<br />muscles)*, numbness and tingling, muscle tense, lack<br />of attention, abnormal taste<br />□ Visual disturbance □ Ringing in ears □ Palpitations<br />□ Hot flush □ Yawning □ Upset stomach,<br />constipation, abdominal pain, vomiting, gas<br />□ Increased sweating, rash □ Back pain, joint pain,<br />muscle pain □ Menstrual irregularities, erectile<br />dysfunction □ Malaise, chest pain, weakness, fever<br />□ Weight increased □ Injury<br />Uncommon (may affect up to 1 in 100 people):<br />□ Gastroenteritis, ear infection □ Tumour<br />□ Hypersensitivity, seasonal allergy □ Low thyroid<br />hormones □ Suicidal thoughts, suicidal behaviour*,<br />psychotic disorder, thinking abnormal, lack of caring,<br />hallucination, aggression, euphoric mood, paranoia<br />□ Amnesia, decreased feeling, involuntar y muscle<br />contractions, passing out, moving a lot, migraine,<br />convulsion, dizziness while standing up, abnormal<br />coordination, speech disorder □ Enlarged pupils<br />□ Ear pain □ Fast heartbeat, heart problem<br />□ Bleeding problems (such as stomach bleeding)*,<br />high blood pressure, flushing, blood in urine<br />□ Shortness of breath, nose bleed, breathing difficulty,<br />possible wheezing □ Tarry stools, tooth disorder,<br />inflammation of the oesophagus, tongue problem,<br />haemorrhoids, increased saliva, difficulty swallowing,<br />burping, tongue disorder □ Eye swelling, hives, hair<br />loss, itching, purple spots on skin, skin problem with<br />blisters, dry skin, face oedema, cold sweat,<br />□ Osteoarthritis, muscle twitching, muscle cramps*,<br />muscular weakness □ Increase in frequency of<br />urination, problem urinating unable to urinate, urinary<br />incontinence, increase in urination, nighttime urination<br />□ Sexual dysfunction, excessive vaginal bleeding,<br />vaginal haemorrhage, female sexual dysfunction<br />□ Swelling in legs, chills, difficulty walking, thirst<br />□ Increase in liver enzyme levels, weight decreased<br />□ Cases of suicidal ideation and suicidal behaviours<br />have been reported during sertraline therapy or early<br />after treatment discontinuation (see section 2).<br />Rare (may affect up to 1 in 1000 people):<br />□ Diverticulitis, swollen lymph glands, decrease in<br />clotting cells*, decrease in white blood cells*<br />□ Severe allergic reaction<br />□ Endocrine problems* □ High cholesterol, problems<br />controlling blood sugar levels (diabetes), low blood<br />sugar, increase in blood sugar levels*, low blood salt*<br />□ Physical symptoms due to stress or emotions,<br />terrifying abnormal dreams*, drug dependence, sleep<br />walking, premature ejaculation<br />□ Coma, abnormal movements, difficulty moving,<br />increased sensation, sudden severe headache (which<br />may be a sign of a serious condition known as<br />reversible cerebral vasoconstriction syndrome<br />(RCVS))*, sensory disturbance<br />□ Spots in front of eyes, glaucoma, double vision, light<br />hurts eye, blood in the eye, unequal sized pupils*,<br />vision abnormal*, tear problem<br />□ Heart attack, light-headedness, fainting, or chest<br />discomfort which could be signs of changes in the<br />electrical activity (seen on electrocardiogram) or<br />abnormal rhythm of the heart*, slow heartbeat □ Poor<br />circulation of arms and legs<br />□ Breathing fast, progressive scarring of lung tissue<br />(interstitial lung disease)*, closing up of throat,<br />difficulty talking, breathing slow, hiccups<br />□ Mouth ulceration, pancreatitis*, blood in stool,<br />tongue ulceration, sore mouth □ Problems with liver<br />function, serious liver function problems*, yellow skin<br />and eyes (jaundice)* □ Skin reaction to sun*, skin<br />oedema*, hair texture abnormal, skin odour abnormal,<br />hair rash □ Breakdown of muscle tissue*, bone<br />disorder □ Urinary hesitation, decreased urination<br />□ Breast discharge, dry vaginal area, genital<br />discharge, red painful penis and foreskin, breast<br />enlargement*, prolonged erection □ hernia, drug<br />tolerance decreased □ Increase in blood cholesterol<br />levels, abnormal laboratory tests*, semen abnormal,<br />problems with clotting* □ Relaxation of blood vessels<br />procedure.<br />Not known: frequency cannot be estimated from<br />the available data:<br />□ Lockjaw* □ Bedwetting* □ Partial loss of vision<br />□ Microscopic colitis (inflammation of the colon that<br />causes persistent watery diarrhea)<br />□ Postpartum hemorrhage**<br />* Side effect reported after marketing.<br />Additional side effects in children and adolescents:<br />In clinical trials with children and adolescents, the side<br />effects were generally similar to adults (see above).<br />The most common side effects in children and<br />adolescents were headache, insomnia, diarrhoea and<br />feeling sick.<br />Symptoms that can occur when treatment is<br />discontinued:<br />If you suddenly stop taking this medicine you may<br />experience side effects such as dizziness, numbness,<br />sleep disturbances, agitation or anxiety, headaches,<br />feeling sick, being sick and shaking (see section 3. &ldquo;If<br />you stop taking SETRAL&rdquo;). An increased risk of bone<br />fractures has been observed in patients taking this<br />type of medicines.<br />* * This event has been reported for the therapeutic<br />class of SSRIs/ SNRIs.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>□ Keep out of the reach and sight of children<br />□ Do not store above 30 &deg;C<br />□ Do not use SETRAL after the expiry date which is<br />stated on the carton and on the blister, after<br />(EXP).Date.<br />Medicines should not be disposed of via wastewater<br />or household waste. Ask your pharmacist how to<br />dispose of medicines no longer required. These<br />measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>□ The active substance is Sertraline. Each SETRAL<br />50 and 100 Film Coated Tablet contains Sertraline 50<br />and 100 mg, respectively, as Sertraline Hydrochloride.<br />□ The other ingredients are: microcrystalline cellulose<br />50 micrometer, anhydrous calcium hydrogen<br />phosphate, sodium starch glycolate type A,<br />hydroxypropyl cellulose, magnesium stearate,<br />hydroxypropyl methylcellulose 2910, polyethylene<br />glycol 400, titanium dioxide, white beeswax</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                □ SETRAL 50 Tablets are white to off-white, circular
shallow biconvex film coated tablet debossed with
“SL50” on one side and plain on the other side.
□ SETRAL 100 Tablets are white to off-white, oval
biconvex film coated tablet with “SL100” debossed on
one side and plain on the other side.
□ Boxes of 10 blistered tablets of SETRAL 50.
□ Boxes of 30 blistered tablets of SETRAL 50.
□ Boxes of 10 blistered tablets of SETRAL 100.
Saudi Arabia: To report any side effect(s): National
Pharmacovigilance Center (NPC): Fax:
+966-11-205-7662, SFDA Call center: 19999, E-mail:
npc.drug@sfda.gov.sa, Website:
https://ade.sfda.gov.sa
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Jordanian pharmaceutical manufacturing co.(P.L.C.|)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي سيترال على المادة الفعالة سيرترالين. يعتبرسيرترالين<br />واحد من مجموعة الأدوية التي تدعى المثبطات الانتقائية<br />لاسترداد السيروتونين والتي تستخدم لعلاج الاكتئاب و/أو<br />اضطرابات القلق.<br />يمكن أن يستخدم سيترال لعلاج الحالات التالية:<br />الاكتئاب والوقاية من تكرار حدوث الاكتئاب (لدى البالغين) □<br />اضطراب ما □ ( اضطراب القلق الاجتماعي (لدى البالغين □<br />اضطراب الهلع (لدى البالغين) □ ( بعد الصدمة (لدى البالغين<br />اضطراب الوسواس القهري (لدى البالغين والأطفال □<br />والمراهقين الذين تتراوح أعمارهم ما بين ٦ إلى ۱۷ سنة).<br />- الاكتئاب هو مرض سريري وأعراضه هي الشعور بالحزن،<br />عدم القدرة على النوم بشكل صحيح أو الاستمتاع بالحياة.<br />- الوسواس القهري واضطرابات الهلع هي حالات مرضية<br />مرتبطة بالقلق مع أعراض مثل الاضطرب المستمر مع أفكار<br />مستمرة (الهواجس) تجعلك تقوم بشعائر متكررة (أفعال قهرية).<br />- اضطراب ما بعد الصدمة هي حالة مرضية تحدث بعد صدمة<br />انفعالية للغاية، ولديها بعض الأعراض المشابهة للاكتئاب والقلق.<br />اضطراب القلق الاجتماعي (الرهاب الاجتماعي) هو مرض<br />مرتبط بالقلق. ويتميز بالشعور بالقلق الشديد أو الاضطراب في<br />المواقف الاجتماعية (مثل، التحدث مع الغرباء، التحدث أمام<br />مجموعة من الأشخاص، تناول الطعام أو الشراب أمام الآخرين<br />أو القلق من أنك قد تتصرف بطريقة محرجة).<br />طبيبك فقط هو الذي يستطيع أن يقرر إذا كان هذا الدواء مناسب<br />لمرضك.<br />عليك أن تسأل طبيبك إذا لم تكن متأكداً من سبب اعطائك سيترال</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>موانع استعمال سيترال:<br />إذا كنت تعاني من حساسية لسيرترالين أو لأي من مكونات □<br />.( سيترال الأخرى ( المذكورة في القسم ٦<br />إذا كنت تتناول أو تناولت الأدوية التي تدعى بمثبطات أكسيداز □<br />أحادي الأمين (مثل سيليجيلين، موكلوبميد) أو الأدوية الشبيهة<br />بمثبطات أكسيداز أحادي الأمين (مثل لينزوليد). إذا قمت بإيقاف<br />المعالجة بسيرترالين، فإنه يجب الانتظار حتى أسبوع واحد على<br />الأقل قبل بدء المعالجة باستخدام مثبطات أكسيداز أحادي الأمين.<br />بعد وقف المعالجة بمثبطات أكسيداز أحادي الأمين فإنه يجب<br />الانتظار حتى أسبوعين على الأقل قبل البدء بالمعالجة باستخدام<br />سيرترالين.<br />إذا كنت تتناول دواء آخر يدعى بيموزايد ( دواء لمعالجة □<br />الاضطرابات العقلية مثل الذهان).<br />الاحتياطات عند استعمال سيترال:<br />تحدث إلى طبيبك او الصيدلاني قبل تناول سيترال.<br />الأدوية لا تكون دائماً مناسبة لجميع الأشخاص. أخبر طبيبك قبل<br />تناول سيترال إذا كنت تعاني أو عانيت مسبقاً من أي من الحالات<br />التالية:<br />إذا كان لديك داء الصرع أو تاريخ من النوبات. اتصل بطبيبك □<br />على الفور إذا عانيت من نوبة.<br />إذا كنت تعاني من اضطراب هوسي اكتئابي (اضطراب ذو □<br />اتجاهين) أو انفصام عقلي. اتصل بطبيبك على الفور إذا كنت<br />تعاني من نوبة هوسية.<br />إذا كان لديك أو قد كان لديك مسبقاً أفكار لإيذاء أو قتل نفسك □<br />(أنظر أدناه، التفكير في الانتحار وتفاقم حالة الاكتئاب أو القلق).<br />إذا كنت تعاني متلازمة السيروتونين، قد تحدث هذه المتلازمة □<br />في حالات نادرة عند تناول أنواع معينة من الأدوية في نفس<br />الوقت الذي تتناول فيه سيرترالين. (للحصول على الأعراض،<br />أنظر إلى قسم ٤، الأعراض الجانبية). سيخبرك طبيبك ما إذا<br />كنت تعاني من هذا المرض في الماضي.<br />إذا كان مستوى الصوديوم لديك منخفض في الدم، لأن ذلك □<br />يحدث نتيجة لاستخدام سيترال. يجب عليك أيضاً أن تخبر طبيبك<br />إذا كنت تتناول أنواع معينة من الأدوية لعلاج ارتفاع ضغط الدم،<br />لأن هذه الأدوية قد تغيرأيضاً من مستوى الصوديوم في الدم.<br />إذا كنت مسناً لأنك قد تكون أكثرعرضة لانخفاض مستوى □<br />الصوديوم في الدم (أنظر أعلاه).<br />إذا كنت تعاني من أمراض الكبد، قد يقرر طبيبك بأنه يجب أن □<br />تتناول جرعة أقل من سيترال.<br />إذا كنت تعاني من مرض السكري، قد تتغير مستويات □<br />الجلوكوز في الدم نتيجة استخدام سيترال لذلك قد يكون هناك<br />حاجة لتعديل أدوية السكري.<br />إذا كنت تعاني من اضطرابات في النزف أوإذا كنت تتناول □<br />أدوية مميعة للدم (مثل، حمض الأسيتيل ساليسيليك (الأسبيرين)،<br />أو وارفارين) أو أدوية تؤدي زيادة خطر النزف.<br />إذا كنت طفلاً أو مراهقاً تحت سن ۱۸ سنة. يجب استخدام □<br />سيترال فقط للأطفال والمراهقين الذين تتراوح أعمارهم ما بين ٦<br />إلى ۱۷ سنة والذين يعانون من الوسواس القهري. إذا كنت تتعالج<br />من هذا الاضطراب فإن طبيبك سيراقبك بشكل دقيق ( أنظر ادناه<br />إلى الأطفال والمراهقين).<br />إذا كنت تخضع للمعالجة بالتخليج الكهربي. □<br />إذا كنت تعاني من مشاكل في العين، مثل أنواع معينة من □<br />الزرق (ارتفاع ضغط العين).<br />إذا تم إخبارك بأنك تعاني من عدم انتظام في ضربات القلب □<br />.QT بعد إجراء مخطط كهربية القلب الذي يعرف بطول فترة ال<br />إذا كنت تعاني من أمراض في القلب، مستوى البوتاسيوم في □<br />الدم قليل أو مستوى المغنيزيوم في الدم قليل، لديك تاريخ عائلي<br />انخفاض معدل ضربات القلب ،QT بمشكلة إطالة فترة ال<br />.QT والإستخدام المتزامن مع الأدوية التي تطول فترة ال<br />الأرق/ التململ: يرتبط استخدام سيرترالين بالأرق الضائق<br />والحاجة إلى التنقل وغالباً ما يكون في عدم المقدرة على الجلوس<br />أو الوقوف دون حراك (التململ). وغالباً ما يحدث هذا خلال<br />الأسابيع القليلة الأولى من المعالجة. قد تكون زيادة الجرعة<br />ضارة، لذلك يجب عليك التحدث إلى طبيبك إذا واجهت مثل هذه<br />الأعراض.<br />الأعراض المتعلقة بوقف المعالجة: الأعراض الجانبية المتعلقة<br />بوقف المعالجة هي أعراض شائعة، لا سيما إذا تم إيقاف المعالجة<br />بشكل مفاجئ (أنظر إلى قسم ۳، التوقف عن تناول سيترال وقسم<br />٤. الأعراض الجانبية). يعتمد خطر الأعراض المتعلقة بوقف<br />المعالجة على طول مدة العلاج، الجرعة وعلى معدل خفض<br />الجرعة. بشكل عام تكون هذه الأعراض خفيفة إلى معتدلة، ومع<br />ذلك فإنها قد تكون خطيرة لدى بعض المرضى. وعادةً ما تحدث<br />خلال الأيام القليلة الأولى من وقف العلاج. وبشكل عام فإن مثل<br />هذه الأعراض تختفي من تلقاء نفسها في غضون أسبوعين، ولدى<br />بعض المرضى قد تستمر لفترة أطول ( ۲ إلى ۳ أشهر أو أكثر).<br />عند وقف المعالجة باستخدام سيرترالين فإنه ينصح بتقليل الجرعة<br />بشكل تدريجي على مدى فترة عدة أسابيع أو أشهر، ويجب أن<br />تناقش أفضل طريقة لوقف العلاج مع طبيبك.<br />التفكير في الانتحار وتفاقم حالة الاكتئاب أو القلق: إذا كنت مكتئباً<br />و/أو تعاني من القلق فقد يكون لديك في بعض الأحيان أفكار<br />لإيذاء أو قتل نفسك. ويمكن أن تزداد هذه الأفكارعند البدء<br />بمضادات الاكتئاب لأول مرة، لأن هذه الأدوية كافة تستغرق وقتاً<br />طويلاً لكي تعمل، عادةً حوالي أسبوعين ولكنها تستغرق وقتاً<br />أطول في بعض الأحيان.<br />قد تكون أكثرعرضة للتفكير في هذا القبيل:<br />إذا كان لديك أفكار سابقة لإيذاء أو قتل نفسك. □<br />إذا كنت من الصغار البالغين. أظهرت التجارب السريرية زيادة □<br />خطر السلوك الانتحاري لدى البالغين الذين أعمارهم تقل عن ۲٥<br />سنة ويعانون من حالات نفسية وتعالجوا باستخدام مضادت<br />الاكتئاب.<br />إذا كانت لديك أفكار لإيذاء أو قتل نفسك في أي وقت، فإن عليك<br />الاتصال مباشرة مع طبيبك أو الذهاب إلى المستشفى مباشرة.<br />قد يكون من المفيد أن تخبر صديقك المقرب أو قريب لك بأنك<br />مصاب بحالة اكتئاب أو قلق، واطلب منهم بأن يقرؤا هذه النشرة<br />وبأن يخبروك في حالة تفاقم حالة الاكتئاب أو القلق لديك أو إذا<br />كانوا يشعرون بالقلق بشأن التغيرات في سلوكك.<br />المشاكل الجنسية:<br />أعراض الخلل (SSRIs قد تسبب أدوية مثل سيترال (أدوية ال<br />الوظيفي الجنسي (انظر القسم ٤). في بعض الحالات، استمرت<br />هذه الأعراض بعد التوقف عن العلاج.<br />الأطفال والمراهقين: لا ينبغي استخدام سيرترالين في الأطفال<br />والمراهقين الذين تقل أعمارهم عن ۱۸ سنة، باستثناء المرضى<br />الذين يعانون من حالة الوسواس القهري. المرضى الذين تقل<br />أعمارهم عن ۱۸ سنة لديهم خطرمتزايد من الأعراض الجانبية،<br />مثل، محاولة الانتحار، أفكار لإيذاء أو قتل أنفسهم (أفكار<br />انتحارية) وعداء (بشكل رئيسي عدوانية وسلوك معارضة<br />وغضب) عندما تتم معالجتهم باستخدام هذه الفئة من الأدوية.<br />وبالرغم من ذلك فإن من المحتمل بأن يصف الطبيب سيترال<br />للمرضى الذين تقل أعمارهم عن ۱۸ سنة إذا كان ذلك من<br />مصلحة المريض. إذا وصف لك طبيبك سيترال وأنت أقل من ۱۸<br />سنة ولديك الرغبة في مناقشة ذلك مع طبيبك يرجى الاتصال به.<br />علاوةً على ذلك، إذا ظهرت أو تفاقمت أي من الأعراض<br />المذكورة أعلاه أثناء تناولك سيترال فإنه يجب عليك إخبار<br />طبيبك. ولم يتم بعد إثبات مأمونية سيرترالين طويلة الأمد فيما<br />يتعلق بالنمو والنضج والتعلم والتطور السلوكي على هذه الفئة<br />العمرية.<br />- قد تزيد المثبطات الإنتقائية لإعادة امتصاص السيروتونين<br />خطر حدوث نزيف ما بعد (SSRI/SNRI) والنورايبينفرين<br />الولادة.<br />تناول سيترال مع أدوية أخرى:<br />إخبر طبيبك أو الصيدلاني إذا كنت تأخذ أو أخذت مؤخراً أو قد<br />تتناول أي أدوية أخرى.<br />يمكن لبعض الأدوية أن تؤثر على الطريقة التي يعمل بها<br />سيترال، أو سيترال نفسه يمكن أن يقلل من فعالية الأدوية الأخرى<br />التي اتخذت في نفس الوقت.<br />تناول سيترال مع الأدوية التالية قد يسبب أعراض جانبية خطيرة:<br />الأدوية التي تسمى مثبطات أوكسيداز أحادي الأمين، مثل، □<br />موكلوبيمايد (لمعالجة الاكتئاب) و سيليجيلين (لمعالجة مرض<br />باركنسون) والمضاد الحيوي لينزوليد و المثيلين الأزرق (لعلاج<br />ارتفاع مستوى الميثيموغلوبين في الدم). لا تتناول هذه الأدوية مع<br />سيترال.<br />الأدوية التي تستخدم لمعالجة الأضطرابات العقلية مثل الذهان □<br />(بيموزيد). لا تتناول سيترال مع بيموزيد.<br />الأدوية التي □ : أخبر طبيبك إذا كنت تتناول أي من الأدوية التالية<br />تحتوي على الأمفيتامينات (المستخدمة لعلاج اضطراب نقص<br />الأدوية □ .( الخدار والسمنة ،(ADHD) الانتباه وفرط الحركة<br />العشبية التي تحتوي على نبتة سانت جون ورت (عشبة<br />هايبريكوم بيرفوراتوم). قد تستمر تأثيرات نبتة سانت جون ورت<br />المستحضرات التي تحتوي على الحمض □ ۲ أسبوع - لمدة ۱<br />الأدوية التي تستخدم لمعالجة الألم الشديد □ الأميني تريبتوفان<br />الأدوية التي تستخدم في التخدير أو □ ( (مثل، ترامادول<br />لمعالجة الألم المزمن (فينتانيل، ميفاكوريوم وسوكساميثونيوم)<br />الأدوية التي تستخدم لمعالجة الصداع النصفي (مثل، □<br />الأدوية □ ( الأدوية المميعة للدم (وارفارين □ ( سوماتريبتان<br />التي تستخدم لمعالجة الألم/ التهاب المفاصل (الأدوية المضادة<br />للالتهاب غير الستيرويدية مثل، الأيبوبروفين، حمض الأسيتيل<br />مدرات البول □ ( مهدئات (دايازيبام □ (( ساليسيليك (الأسبيرين<br />الأدوية التي تستخدم لعلاج الصرع (فينيتوين، فينوباربيتال، □<br />الأدوية التي تستخدم لمعلجة السكري □ ( كاربامازبين<br />الأدوية التي تستخدم لمعالجة حمض المعدة □ ( (تولبوتامايد<br />الزائد، القرحات وحرقة المعدة (سيميتيدين، أومبرازول،<br />الأدوية التي □ ( لانزوبرازول، بانتوبرازول، رابيبرازول<br />الأدوية □ ( تستخدم لمعالجة الهوس والاكتئاب (الليثيوم<br />الأخرى التي تستخدم لمعالجة الاكتئاب (مثل، أميتريبتيلين،<br />الأدوية □ ( نورتريبتيلين، نيفازودون، فلوكسيتين، فلوفوكسامين<br />التي تستخدم لمعالجة الانفصام العقلي والاضطرابات العقلية<br />الأخرى (مثل بيرفينازين و ليفوميبرومازين و أولانزابين)<br />الأدوية التي تستخدم لعلاج ارتفاع ضغط الدم، الآم الصدرأو □<br />لتنظيم معدل ضربات القلب (مثل فيراباميل، ديالتيزم، فليسيانيد،<br />الأدوية التي تستخدم لعلاج العدوى البكتيرية □ ( بروبافينون<br />(مثل ريفامبيسين، كلاريثرومايسين، تيلثرومايسين،<br />الادوية التي تستخدم لعلاج العدوى الفطرية □ ( إريثرومايسين<br />(مثل، كيتوكونازول، ايتراكونازول، بويزاكونازول،<br />الأدوية التي تستخدم لعلاج □ ( فوريكونازول، فلوكونازول<br />فيروس نقص المناعة البشرية/الإيدز ولعلاج التهاب الكبد الوبائي<br />الأدوية □ ( نوع ج (مثبطات البروتياز مثل، ريتونافير، تيلبريفير<br />التي تستخدم لمنع الغثيان والقيء بعد العملية أو العلاج الكيميائي<br />الادوية التي تسبب زيادة خطر التغيراب في □ ( (أبريبيتانت<br />النشاط الكهربائي للقلب ( مثل مضادات الذهان و المضادات<br />الحيوية).<br />تناول سيترال مع الطعام، الشراب والكحول:<br />ينبغي □ يمكن تناول أقراص سيترال مع الطعام أو بدونه □<br />لا ينبغي تناول عصير □ تجنب الكحول أثناء تناول سيترال<br />الجريب فروت مع سيرترالين لأن ذلك يؤدي إلى زيادة مستوى<br />السيرترالين في الجسم.<br />الحمل، الرضاعة والخصوبة:<br />إذا كنت حاملاً أو مرضعة أو تعتقدين بأنك حامل أو تخططين<br />للإنجاب، تحدثي مع طبيبك أو الصيدلي للحصول على المشورة<br />قبل تناول هذا الدواء.<br />لم تثبت مأمونية سيرترالين بشكل كامل لدى النساء الحوامل. سيتم<br />إعطاء سيرترالين للنساء الحوامل فقط إذا اعتبر طبيبك بأن الفائدة<br />من تناوله هي أكبر من أي خطر محتمل على تطور الجنين. يجب<br />التأكد من أن القابلة و/أو طبيبك على معرفة بأنك تتناولين<br />سيترال. عند تناول سيترال أثناء الحمل وخاصةً في الأشهر<br />الثلاثة الأخيرة من الحمل فإنه قد يؤدي إلى زيادة خطر حدوث<br />حالة خطيرة للجنين والتي تسمى ارتفاع ضغط الدم الرئوي<br />المستديم لحديثي الولادة، مما يجعل الجنين يتنفس بشكل سريع<br />ويبدو مزرق. عادةً تبدأ هذه الأعراض أثناء ۲٤ ساعة الأولى بعد<br />ولادة الطفل. إذا حدث ذلك لطفلك فإن عليك الاتصال بالقابلة و/أو<br />الطبيب على الفور.<br />قد يعاني طفلك أيضاً من حالات أخرى والتي تبدأ عادةً أثناء ۲٤<br />ساعة الأولى من الولادة والتي تشمل الأعراض التالية:<br />ازرقاق الجلد، أو يصبح ساخن جداً أو □ مشكلة في التنفس □<br />قيء أو عدم تغذية الجنين بشكل □ شفاه زرقاء □ بارد<br />تعب الجنين بشكل شديد وعدم مقدرته على النوم أو □ صحيح<br />رعاش، ارتعاش □ تصلب أو مرونة العضلات □ البكاء بشدة<br />انخفاض □ تهيج □ زيادة ردود الفعل العكسية □ أو نوبات<br />السكر في الدم<br />إذا كان لطفلك أي من هذه الأعراض عند ولادته أو كنت تشعرين<br />بالقلق حول صحة طفلك فإن عليك الاتصال بالطبيب أو القابلة<br />الذين سيكونون قادرين على تقديم النصيحة لك.<br />هناك أدلة على أن سيرترالين يمر في حليب الأم. يجب استخدام<br />سيرترالين أثناء الرضاعة فقط إذا اعتبر الطبيب بأن الفائدة من<br />استخدامه تفوق أي خطر محتمل للطفل.<br />تبين في الدراسات الحيوانية أن بعض الأدوية مثل سيرترالين قد<br />تقلل نوعية الحيوانات المنوية. ومن الناحية النظرية، يمكن أن<br />يؤثر ذلك على الخصوبة، ولكن لم يلاحظ حتى الآن التأثير على<br />الخصوبة البشرية.<br />المعلومات الرصدية تشير إلى إزدياد خطر حدوث نزيف ما بعد<br />SSRI/SNRI الولادة (أقل من ۲ ضعف) بعد التعرض لأدوية<br />خلال شهر قبل الولادة.<br />تأثير المستحضر على القيادة واستخدام الآلات:<br />قد تؤثر الأدوية ذات التأثير النفساني مثل السيرترالين على قدرتك<br />في القيادة أو على استخدام الآلات، لذلك لا يجب أن تقود أو<br />تستخدم الآلات حتى تتعرف على تأثير هذا الدواء على قدرتك في<br />إنجاز هذه الأنشطة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائماً تناول الدواء تماماً كما أخبرك طبيبك أو الصيدلاني. □<br />تحقق من طبيبك أو الصيدلي إذا لم تكن متاكداً. □<br />الجرعة التي ينصح بها للبالغين:<br />الاكتئاب واضطراب الوسواس القهري: الجرعة الاعتيادية □<br />الفعالة لمعالجة الاكتئاب والوسواس القهري ٥۰ ملغم/يوم. يمكن<br />زيادة الجرعة اليومية بمقدار ٥۰ ملغم خلال فترة لا تقل عن<br />أسبوع واحد على مدى أسابيع. الجرعة القصوى الموصى بها<br />هي ۲۰۰ ملغم/يوم.<br />اضطراب الهلع واضطراب القلق الاجتماعي و اضطراب ما □<br />بعد الصدمة: يجب أن تبدأ المعالجة لاضطراب الهلع واضطراب<br />القلق الاجتماعي واضطراب ما بعد الصدمة بجرعة ۲٥<br />ملغم/يوم، وتزداد إلى ٥۰ ملغم/يوم بعد أسبوع واحد، ثم يمكن<br />زيادة الجرعة اليومية بمقدار ٥۰ ملغم على مدى أسابيع. الجرعة<br />القصوى الموصى بها هي ۲۰۰ ملغم/يوم.<br />الاستخدام في الأطفال والمراهقين: يجب استخدام سيترال فقط<br />للأطفال والمراهقين الذين تتراوح أعمارهم ما بين ٦ و ۱۷ سنة<br />لعلاج الوسواس القهري.<br />اضطراب الوسواس القهري:<br />الأطفال الذين تتراوح أعمارهم من ٦ إلى ۱۲ سنة: جرعة □<br />البدء الموصى بها هي ۲٥ ملغم يومياً. قد يزيد لك الطبيب<br />الجرعة بعد أسبوع واحد لتصل إلى ٥۰ ملغم يومياً. الجرعة<br />القصوى الموصى بها هي ۲۰۰ ملغم يومياً.<br />المراهقين الذين تتراوح أعمارهم من ۱۳ إلى ۱۷ سنة: جرعة □<br />البدء الموصى بها هي ٥۰ ملغم يومياً. الجرعة القصوى الموصى<br />بها هي ۲۰۰ ملغم يومياً.<br />يرجى إخبار طبيبك واتباع تعليماته إذا كنت تعاني من مشاكل في<br />الكبد أو الكلى.<br />طريقة الإعطاء:<br />تناول □ يمكن تناول اقراص سيترال مع أو بدون الطعام □<br />دوائك مرة واحدة في اليوم سواء في الصباح أو المساء<br />سينصحك طبيبك عن المدة التي يجب أن تتناول فيها الدواء، وهذا<br />يعتمد على طبيعة مرضك وعلى استجابتك للعلاج، فقد تحتاج إلى<br />عدة أسابيع قبل أن تبدأ الأعراض بالتحسن. علاج الاكتئاب يجب<br />أن يستمرعادةً إلى ٦ أشهر بعد التحسن.<br />الجرعة الزائدة من سيترال: اتصل بطبيبك على الفور أو اذهب<br />إلى أقرب قسم طوارئ إذا تناولت عن غير قصد كمية كبيرة من<br />سيترال. دائماً خذ معك علبة الدواء سواء كانت تحتوي على دواء<br />أو لا.<br />قد تشمل أعراض الجرعة الزائدة النعاس والغثيان والقيء، زيادة<br />معدل ضربات القلب، رعاش، هياج، دوخة، وفي حالات نادرة<br />فقدان الوعي.<br />نسيان تناول سيترال: إذا نسيت أن تتناول الجرعة فلا تتناولها،<br />فقط عليك تناول الجرعة التالية في وقتها الصحيح. لا تتناول<br />جرعة مضاعفة لتعويض الجرعة المنسية.<br />التوقف عن تناول سيترال: لا تتوقف عن تناول سيترال ما لم<br />يخبرك طبيبك بذلك. سيقلل طبيبك جرعة سيترال بشكل تدريجي<br />خلال عدة أسابيع، قبل التوقف عن تناول هذا الدواء بشكل نهائي.<br />إذا توقفت عن تناول الدواء بشكل مفاجىء فقد تواجه أعراضاً<br />جانبية مثل الدوخة، الخدر، اضطرابات في النوم، هياج أو القلق،<br />صداع، الشعور بالمرض، المرض، رعاش. يرجى التحدث<br />لطبيبك إذا واجهت أي من هذه الأعراض الجانبية أو أي أعراض<br />أخرى أثناء التوقف عن تناول سيترال.<br />اسأل طبيبك أو الصيدلي إذا كان لديك أي أسئلة أخرى حول<br />استعمال هذا المستحضر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كغيره من الأدوية فإن سيترال قد يسبب أعراضاً جانبية بالرغم<br />من أنها لاتحدث للجميع.<br />الغثيان هو أكثر الأعراض الجانبية شيوعاً. تعتمد الأعراض<br />الجانبية على الجرعة وعادةً ما تختفي أو تقل مع استمرار العلاج.<br />أخبر طبيبك على الفور، إذا واجهتك أي من الأعراض التالية بعد<br />تناول هذا الدواء فإن هذه الأعراض قد تكون خطيرة:<br />إذا عانيت من طفح جلدي شديد الذي يسبب تقرحات (حمامى □<br />عديدة الأشكال) (وهذا يمكن أن يؤثر على الفم واللسان). قد تكون<br />هذه علامات على حالة مرضية تعرف بمتلازمة ستيفنز جونسون<br />أو تقشر الأنسجة المتموتة البشروية التسممي. سيوقف طبيبك<br />العلاج في مثل هذه الحالات.<br />تفاعلات تحسسية أو حساسية والتي قد تشمل أعراض مثل □<br />طفح جلدي وحكة، مشاكل تنفسية، صفير عند التنفس، تورم<br />الجفون، الوجه أو الشفاه.<br />إذا عانيت من هياج، ارتباك، إسهال، ارتفاع درجة الحرارة □<br />وضغط الدم، تعرق شديد وتسارع نبضات القلب وهذه هي<br />أعراض متلازمة السيروتونين. في حالات نادرة قد تحدث هذه<br />المتلازمة عند تناول أدوية معينة في الوقت نفسه مع سيرترالين.<br />قد يرغب طبيبك في وقف المعالجة.<br />إذا عانيت من اصفرار في الجلد والعينين وهو ما قد يعني تلف □<br />في الكبد.<br />إذا عانيت من أعراض الاكتئاب مع أفكار لإيذاء أو قتل نفسك □<br />(أفكار انتحارية).<br />إذا بدأت بالشعور بالأرق وعدم القدرة على الجلوس أو □<br />الوقوف دون حراك بعد البدء بتناول سيترال. يجب أن تخبر<br />طبيبك إذا بدأت بالشعور في التململ.<br />إذا عانيت من نوبة هوس (انظر □ . إذا عانيت من نوبة □<br />إلى قسم ۲ &quot; الاحتياطات عند استعمال سيترال&quot;).<br />الأعراض الجانبية التالية التي ظهرت في التجارب السريرية<br />وبعد التسويق على البالغين:<br />الأعراض الجانبية الشائعة جداً (قد تؤثر على أكثر من شخص<br />من ۱۰ أشخاص): أرق، دوخة، نعاس، صداع، إسهال،<br />الشعور بالمرض، جفاف الفم، فشل القذف، تعب.<br />الأعراض الجانبية الشائعة (قد تؤثر على ما يصل إلى شخص<br />واحد من ۱۰ أشخاص):<br />قلة الشهية، □ نزلة صدرية، احتقان الحلق، سيلان الأنف □<br />قلق، اكتئاب، هياج، انخفاض الاهتمام الجنسي، □ زيادة الشهية<br />اهتزاز، □ توتر، الشعور بالغرابة، كابوس، صرير الأسنان<br />مشاكل في الحركة العضلية (مثل الحركة كثيراً، توتر العضلات،<br />صعوبة في المشي والتصلب، تشنجات وحركات لا إرادية<br />للعضلات) *، خدر ووخز، توتر عضلي، قلة الانتباه، طعم غير<br />رنين في الأذنين □ اضطرابات بصرية □ طبيعي<br />اضطراب المعدة، □ تثاءب □ هبات ساخنة □ خفقان □<br />زيادة التعرق والطفح □ إمساك، آلام في البطن، تقيؤ، غازات<br />عدم □ آلام الظهر، آلام المفاصل، آلام العضلات □ الجلدي<br />الشعور بالضيق، □ انتظام الدورة الشهرية، ضعف الانتصاب<br />إصابة □ زيادة الوزن □ ألم في الصدر، ضعف، حمى<br />الأعراض الجانبية الغير الشائعة (قد تؤثر على ما يصل إلى<br />شخص واحد من ۱۰۰ شخص):<br />فرط □ ورم □ التهاب المعدة والأمعاء، التهاب الأذن □<br />انخفاض هرمونات الغدة □ الحساسية، حساسية موسمية<br />أفكار انتحارية، سلوك انتحاري *، اضطراب ذهاني، □ الدرقية<br />تفكير غير طبيعي، نقص في الإهتمام، هلوسة، عدوانية، مزاج<br />فقدان الذاكرة، انخفاض الشعور، □ مبهج، جنون العظمة<br />تقلصات العضلات اللاإرادية، الإغماء، التحرك كثيراً، الصداع<br />النصفي، تشنج ، دوخة أثناء الوقوف، التنسيق غير الطبيعي،<br />سرعة □ ألم الأذن □ توسع البؤبؤ □ اضطراب الكلام<br />مشاكل النزيف (مثل نزيف □ ضربات القلب، مشكلة في القلب<br />المعدة) *، ارتفاع ضغط الدم، توهج، دم في البول<br />ضيق في التنفس، نزيف من الأنف، صعوبة في التنفس، □<br />لون البراز مثل القطران، مشاكل الأسنان، □ صفير محتمل<br />التهاب المريء، مشكلة في اللسان، بواسير، زيادة اللعاب،<br />صعوبة البلع، التجشؤ، اضطراب في اللسان<br />تورم العين، شرى، تساقط الشعر، حكة، بقع أرجوانية على □<br />الجلد، مشكلة في الجلد مع بثور، جفاف الجلد، وذمة الوجه،<br />هشاشة العظام، ارتعاش العضلات، تشنجات □ العرق البارد<br />العضلات، ضعف العضلات<br />زيادة في عدد مرات التبول، مشكلة في التبول عدم القدرة على □<br />التبول، سلس البول، زيادة التبول، التبول الليلي<br />الخلل الجنسي، النزيف المهبلي المفرط، النزيف المهبلي، □<br />تورم في الساقين، قشعريرة، صعوبة □ الخلل الجنسي الأنثوي<br />زيادة في مستويات انزيمات الكبد، □ في المشي، عطش<br />تم الإبلاغ عن حالات التفكير الانتحاري □ انخفاض الوزن<br />والسلوكيات الانتحارية أثناء العلاج بإستخدام سيرترالين أو في<br />.( وقت مبكر بعد التوقف عن العلاج (انظر القسم ۲<br />الأعراض الجانبية النادرة (قد تؤثر على ما يصل إلى شخص<br />واحد من ۱۰۰۰ شخص):<br />التهاب الرتج، تورم الغدد اللمفاوية، انخفاض خلايا التخثر *، □<br />رد فعل تحسسي شديد □ * انخفاض خلايا الدم البيضاء<br />ارتفاع نسبة الكوليسترول، مشاكل □ * مشاكل الغدد الصماء □<br />في التحكم في مستويات السكر في الدم (السكري)، انخفاض نسبة<br />السكر في الدم، زيادة مستويات السكر في الدم *، انخفاض<br />أعراض جسدية بسبب الإجهاد أو □ * مستوى الأملاح في الدم<br />العواطف، أحلام مرعبة غير طبيعية *، الاعتماد على<br />المخدرات، المشي أثناء النوم، القذف المبكر<br />غيبوبة، حركات غير طبيعية، صعوبة في الحركة، زيادة □<br />الإحساس، صداع حاد مفاجئ (قد يكون علامة على حالة خطيرة<br />تعرف باسم متلازمة تضيق الأوعية الدماغية العكسية<br />اضطراب حسي ،* ((RCVS)<br />بقع أمام العين، ارتفاع ضغط العين، الرؤية المزدوجة، الضوء □<br />يؤذي العين، دم في العين، بؤبؤ العينين غير المتساويين الحجم *،<br />الرؤية غير طبيعية *، مشكلة في الدمع<br />نوبة قلبية، دوار خفيف، إغماء، انزعاج في الصدر يمكن أن □<br />يكون علامات على تغيرات في النشاط الكهربائي (يظهر على<br />مخطط كهربية القلب) أو إيقاع غير طبيعي في القلب *، أو بطء<br />ضعف الدورة الدموية في الذراعين والساقين □ ضربات القلب<br />التنفس السريع، التندب التدريجي لأنسجة الرئة (مرض الرئة □<br />الخلالي) *، إغلاق الحلق، صعوبة في الكلام، التنفس البطيء،<br />تقرح الفم، التهاب البنكرياس *، دم في البراز، تقرح □ حازوقة<br />مشاكل في وظائف الكبد، مشاكل خطيرة □ اللسان، التهاب الفم<br />في وظائف الكبد *، اصفرار الجلد والعينين (اليرقان) *<br />تفاعل الجلد مع الشمس *، وذمة الجلد *، ملمس غير طبيعي □<br />للشعر، رائحة الجلد غير طبيعية، طفح الشعر<br />تردد □ انهيار أنسجة العضلات *، اضطراب العظام □<br />البول، انخفاض التبول<br />إفرازات الثدي، جفاف منطقة المهبل، إفرازات الأعضاء □<br />التناسلية، إحمرار القضيب والقلفة المؤلم، تضخم الثدي *،<br />الانتصاب لفترات طويلة<br />زيادة مستويات الكوليسترول □ فتق، انخفض تحمل الدواء □<br />في الدم، الاختبارات المعملية غير الطبيعية *، السائل المنوي<br />غير الطبيعي، مشاكل التخثر*<br />استرخاء الأوعية الدموية. □<br />أعراض جانبية غير معروفة: لا يمكن تقدير تكرار حدوثها من<br />البيانات المتاحة:<br />فقدان جزئي للرؤية □ * التبول اللاإرادي □ * الكزاز □<br />التهاب القولون الذي يسبب اسهال مائي مستمر. □<br />نزيف ما بعد الولادة.** □<br />* أعراض جانبية تم الإبلاغ عنها بعد التسويق.<br />أعراض جانبية إضافية في الأطفال والمراهقين: الأعراض<br />الجانبية التي ظهرت في التجارب السريرية على الأطفال<br />والمراهقين كانت مشابهة بشكل عام للأعراض التي ظهرت على<br />البالغين (انظر أعلاه). الأعراض الجانبية الأكثر شيوعاً في<br />الأطفال والمراهقين هي صداع، أرق، إسهال، والشعور<br />بالمرض.<br />الأعراض التي قد تحدث عند وقف المعالجة: قد تواجه<br />الأعراض الجانبية التالية إذا توقفت عن المعالجة بشكل مفاجيء<br />مثل الدوخة، الخدر، اضطرابات النوم، هياج أو قلق، صداع،<br />الشعور بالمرض، المرض، ورعاش (أنظر إلى قسم ۳ &quot; التوقف<br />عن تناول سيترال&quot;).<br />وقد لوحظ زيادة خطر الكسور العظمية في المرضى الذين<br />يتناولون هذا النوع من الأدوية.<br />** تم الإبلاغ عن هذا العرض للفئة العلاجية لأدوية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><br />لا يحفظ بدرجة حرارة □ يحفظ بعيداً عن متناول الأطفال □<br />لا ينبغي استعمال سيترال بعد تاريخ انتهاء □ أعلى من ۳۰ &deg;م<br />الصلاحية الموجود على العلبة وعلى شريط الدواء.<br />لا ينبغي التخلص من الأدوية من خلال مياه الصرف الصحي أو<br />المنزلي. اسأل الصيدلاني عن كيفية التخلص من الأدوية التي لم<br />تعد مطلوبة. سوف تساعد هذه الاجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي سيرترالين. كل قرص مغلف من أقراص □<br />سيترال ٥۰ و ۱۰۰ يحتوي على ٥۰ و ۱۰۰ ملغم من سيرترالين<br />على التوالي، على هيئة سيرترالين هيدروكلورايد.<br />المكونات الأخرى هي: سليولوز بلوري مكروي ٥۰ □<br />ميكروميتر، فسفات هيدروجين الكالسيوم اللامائية، جليكولات نشا<br />هيدروكسي بروبيل سليولوز، ستيارات ،(A الصوديوم (نوع<br />المغنيزيوم، هيدروكسي بروبيل ميثيل سليولوز ۲۹۱۰ ، بولي<br />إيثيلين جلايكول ٤۰۰ ، ثاني أكسيد التيتانيوم، شمع العسل<br />الأبيض.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><br /><strong>أقراص سيترال ٥۰ هي أقراص مغلفة بيضاء إلى سكرية □<br />من &rdquo;SL اللون دائرية ضحلة ثنائية التحدب منقوش عليها &rdquo; ٥۰<br />جانب واحد و غير منقوشة من الجانب الآخر.<br />أقراص سيترال ۱۰۰ هي أقراص مغلفة بيضاء إلى سكرية □<br />من جانب &rdquo;SL اللون بيضوية ثنائية التحدب منقوش عليها &rdquo; ۱۰۰<br />واحد و غير منقوشة من الجانب الآخر.<br />علب تحتوي على ۱۰ أقراص من سيترال ٥۰ محفوظة في □<br />أشرطة.<br />علب تحتوي على ۳۰ قرص من سيترال ٥۰ محفوظة في □<br />أشرطة.<br />علب تحتوي على ۱۰ أقراص من سيترال ۱۰۰ محفوظة في □<br />أشرطة.<br />المملكة العربية السعودية: للإبلاغ عن الأعراض الجانبية:<br />المركزالوطني للتيقظ: فاكس: ۰۰۹٦٦۱۱۲۰٥۷٦٦۲ ، مركز<br />۱۹۹۹۹ ، البريد :(SFDA) اتصال الهيئة العامة للغذاء والدواء<br />الموقع ،npc.drug@sfda.gov.sa : الإلكتروني<br />https://ade.sfda.gov.sa : الإلكتروني</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشركة الاردنية لانتاج الادوية المساهمة العامة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تشرين الثاني ۲۰۲۰
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SETRAL 50mg Film-Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active ingredient:
50 mg Sertraline film-coated tablets
Inactive ingredients:
Ingredient Quantity
mg/tab.
Microcrystalline Cellulose 50 micrometer 53
Anhydrous Calcium Hydrogen Phosphate 15.19
Sodium Starch Glycolate (Type A) 10
Hydroxypropyl Cellulose (Klucel EF) 03.5
Magnesium Stearate 00.99
Hydroxypropyl Methylcellulose Type 2910
(Methocel E5)
3.31
Polyethylene Glycol 400 0.33
Titanium Dioxide 01.36
White Beeswax Polish
*For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SETRAL 50 mg is White to off white, circular shallow biconvex film coated
tablet debossed with “SL 50” on one side and plain on the other side.
SPC SETRAL 50 mg Film Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SETRAL is indicated for the treatment of:<br /> Major depressive episodes. Prevention of recurrence of major<br />depressive episodes.<br /> Panic disorder, with or without agoraphobia.<br /> Obsessive compulsive disorder (OCD) in adults and paediatric<br />patients aged 6-17 years.<br /> Social anxiety disorder.<br /> Post traumatic stress disorder (PTSD).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Initial treatment<br /> Depression and OCD<br />Sertraline treatment should be started at a dose of 50 mg/day.<br /> Panic Disorder, PTSD, and Social Anxiety Disorder<br />Therapy should be initiated at 25 mg/day. After one week, the dose should<br />be increased to 50 mg once daily. This dosage regimen has been shown to<br />reduce the frequency of early treatment emergent side effects characteristic<br />of panic disorder.<br />Titration<br /> Depression, OCD, Panic Disorder, Social Anxiety Disorder and<br />PTSD<br />Patients not responding to a 50 mg dose may benefit from dose increases.<br />Dose changes should be made in steps of 50 mg at intervals of at least one<br />week, up to a maximum of 200 mg/day. Changes in dose should not be<br />made more frequently than once per week given the 24-hour elimination<br />half life of Sertraline.<br />The onset of therapeutic effect may be seen within 7 days. However,<br />longer periods are usually necessary to demonstrate therapeutic response,<br />especially in OCD.<br />Maintenance<br />Dosage during long-term therapy should be kept at the lowest effective<br />level, with subsequent adjustment depending on therapeutic response.<br />SPC SETRAL 50 mg Film Coated Tablets<br /> Depression<br />Longer-term treatment may also be appropriate for prevention of<br />recurrence of major depressive episodes (MDE). In most of the cases, the<br />recommended dose in prevention of recurrence of MDE is the same as the<br />one used during current episode. Patients with depression should be treated<br />for a sufficient period of time of at least 6 months to ensure they are free<br />from symptoms.<br /> Panic disorder and OCD<br />Continued treatment in panic disorder and OCD should be evaluated<br />regularly, as relapse prevention has not been shown for these disorders.<br />Elderly patients<br />Elderly should be dosed carefully, as elderly may be more at risk for<br />hyponatraemia (see section 4.4).<br />Patients with hepatic impairment<br />The use of Sertraline in patients with hepatic disease should be approached<br />with caution. A lower or less frequent dose should be used in patients with<br />hepatic impairment (see section 4.4). Sertraline should not be used in cases<br />of severe hepatic impairment as no clinical data are available (see section<br />4.4)<br />Patients with renal impairment<br />No dosage adjustment is necessary in patients with renal impairment (see<br />section 4.4).<br />Paediatric population<br />Children and adolescents with obsessive compulsive disorder<br /> Age 13-17 years: Initially 50 mg once daily.<br /> Age 6-12 years: Initially 25 mg once daily. The dosage may be<br />increased to 50 mg once daily after one week.<br />Subsequent doses may be increased in case of less than desired response in<br />50 mg increments over a period of some weeks, as needed. The maximum<br />dosage is 200 mg daily. However, the generally lower body weights of<br />children compared to those of adults should be taken into consideration<br />when increasing the dose from 50 mg. Dose changes should not occur at<br />intervals of less than one week.<br />Efficacy is not shown in paediatric major depressive disorder.<br />No data is available for children under 6 years of age (see also section 4.4).<br />Method of administration<br />Sertraline should be administered once daily, either in the morning or<br />evening.<br />Sertraline tablet can be administered with or without food.<br />SPC SETRAL 50 mg Film Coated Tablets<br />Withdrawal symptoms seen on discontinuation of Sertraline<br />Abrupt discontinuation should be avoided. When stopping treatment with<br />Sertraline the dose should be gradually reduced over a period of at least<br />one to two weeks in order to reduce the risk of withdrawal reactions (see<br />sections 4.4 and 4.8). If intolerable symptoms occur following a decrease<br />in the dose or upon discontinuation of treatment, then resuming the<br />previously prescribed dose may be considered. Subsequently, the<br />physician may continue decreasing the dose, but at a more gradual rate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or any of the excipients
listed in section 6.1.
 Concomitant treatment with irreversible monoamine oxidase
inhibitors (MAOIs) is contraindicated due to the risk of serotonin
syndrome with symptoms such as agitation, tremor and
hyperthermia. Sertraline must not be initiated for at least 14 days
after discontinuation of treatment with an irreversible MAOI.
Sertraline must be discontinued for at least 7 days before starting
treatment with an irreversible MAOI (see section 4.5).
 Concomitant intake of pimozide is contraindicated (see section
4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Serotonin Syndrome (SS) or Neuroleptic Malignant Syndrome<br />(NMS)<br />The development of potentially life-threatening syndromes like<br />serotonin syndrome (SS) or Neuroleptic Malignant Syndrome (NMS)<br />has been reported with SSRIs, including treatment with sertraline. The<br />risk of SS or NMS with SSRIs is increased with concomitant use of<br />other serotonergic drugs (including other serotonergic antidepressants,<br />amphetamines, triptans), with drugs which impair metabolism of<br />serotonin (including MAOIs e.g. methylene blue), antipsychotics and<br />other dopamine antagonists, and with opiate drugs. Patients should be<br />monitored for the emergence of signs and symptoms of SS or NMS<br />syndrome (see section 4.3).<br /> Switching from Selective Serotonin Reuptake Inhibitors (SSRIs),<br />antidepressants or anti-obsessional drugs<br />There is limited controlled experience regarding the optimal timing of<br />switching from SSRIs, antidepressants or anti-obsessional drugs to<br />Sertraline. Care and prudent medical judgment should be exercised<br />when switching, particularly from long-acting agents such as<br />fluoxetine.<br />SPC SETRAL 50 mg Film Coated Tablets<br /> Other serotonergic drugs e.g. tryptophan, fenfluramine and 5-HT<br />agonists<br />Co-administration of Sertraline with other drugs which enhance the<br />effects of serotonergic neurotransmission such as tryptophan or<br />fenfluramine or 5-HT agonists, or the herbal medicine, St John&#39;s Wort<br />(hypericum perforatum), should be undertaken with caution and<br />avoided whenever possible due to the potential for a pharmacodynamic<br />interaction.<br /> QTc Prolongation/Torsade de Pointes (TdP)<br />Cases of QTc prolongation and TdP have been reported during postmarketing<br />use of sertraline. The majority of reports occurred in patients<br />with other risk factors for QTc prolongation/TdP. Effect on QTc<br />prolongation was confirmed in a thorough QTc study in healthy<br />volunteers, with a statistically significant positive exposure response<br />relationship. Therefore, sertraline should be used with caution in<br />patients with additional risk factors for QTc prolongation such as<br />cardiac disease, hypokalaemia or hypomagnesemia, familial history of<br />QTc prolongation, bradycardia and concomitant use of medications<br />which prolong QTc interval (see sections 4.5 and 5.1).<br /> Activation of hypomania or mania<br />Manic/hypomanic symptoms have been reported to emerge in a small<br />proportion of patients treated with marketed antidepressant and antiobsessional<br />drugs, including Sertraline. Therefore, Sertraline should be<br />used with caution in patients with a history of mania/hypomania. Close<br />surveillance by the physician is required. Sertraline should be<br />discontinued in any patient entering a manic phase.<br /> Schizophrenia<br />Psychotic symptoms might become aggravated in schizophrenic<br />patients.<br /> Seizures<br />Seizures may occur with Sertraline therapy: Sertraline should be<br />avoided in patients with unstable epilepsy and patients with controlled<br />epilepsy should be carefully monitored. Sertraline should be<br />discontinued in any patient who develops seizures.<br /> Suicide/suicidal thoughts/suicide attempts or clinical worsening<br />Depression is associated with an increased risk of suicidal thoughts,<br />self harm and suicide (suicide-related events). This risk persists until<br />significant remission occurs. As improvement may not occur during<br />the first few weeks or more of treatment, patients should be closely<br />SPC SETRAL 50 mg Film Coated Tablets<br />monitored until such improvement occurs. It is general clinical<br />experience that the risk of suicide may increase in the early stages of<br />recovery.<br />Other psychiatric conditions, for which Sertraline is prescribed, can<br />also be associated with an increased risk of suicide-related events. In<br />addition, these conditions may be co-morbid with major depressive<br />disorder. The same precautions observed when treating patients with<br />major depressive disorder should therefore be observed when treating<br />patients with other psychiatric disorders.<br />Patients with a history of suicide-related events, or those exhibiting a<br />significant degree of suicidal ideation prior to commencement of<br />treatment are known to be at greater risk of suicidal thoughts or suicide<br />attempts, and should receive careful monitoring during treatment. A<br />meta-analysis of placebo-controlled clinical trials of antidepressant<br />drugs in adult patients with psychiatric disorders showed an increased<br />risk of suicidal behaviour with antidepressants compared to placebo in<br />patients less than 25 years old.<br />Close supervision of patients and in particular those at high risk should<br />accompany drug therapy especially in early treatment and following<br />dose changes. Patients (and caregivers of patients) should be alerted<br />about the need to monitor for any clinical worsening, suicidal<br />behaviour or thoughts and unusual changes in behaviour and to seek<br />medical advice immediately if these symptoms present.<br /> Paediatrec population<br />Sertraline should not be used in the treatment of children and<br />adolescents under the age of 18 years, except for patients with<br />obsessive compulsive disorder aged 6-17 years old. Suicide-related<br />behaviours (suicide attempt and suicidal thoughts), and hostility<br />(predominantly aggression, oppositional behaviour and anger) were<br />more frequently observed in clinical trials among children and<br />adolescents treated with antidepressants compared to those treated with<br />placebo. If, based on clinical need, a decision to treat is nevertheless<br />taken; the patient should be carefully monitored for appearance of<br />suicidal symptoms. In addition only limited clinical evidence is<br />available concerning, long-term safety data in children and adolescents<br />including effects on growth, sexual maturation and cognitive and<br />behavioural developments. A few cases of retarded growth and delayed<br />puberty have been reported post-marketing. The clinical relevance and<br />causality are yet unclear (see section 5.3 for corresponding preclinical<br />safety data). Physicians must monitor paediatric patients on long term<br />treatment for abnormalities in growth and development.<br /> Abnormal bleeding/Haemorrhage<br />There have been reports of bleeding abnormalities with SSRIs<br />including cutaneous bleeding (ecchymoses and purpura) and other<br />SPC SETRAL 50 mg Film Coated Tablets<br />haemorrhagic events such as gastrointestinal or gynaecological<br />bleeding, including fatal haemorrhages. Caution is advised in patients<br />taking SSRIs, particularly in concomitant use with drugs known to<br />affect platelet function (e.g. anticoagulants, atypical antipsychotics and<br />phenothiazines, most tricyclic antidepressants, acetylsalicylic acid and<br />non-steroidal anti-inflammatory drugs (NSAIDs)) as well as in patients<br />with a history of bleeding disorders (see section 4.5).<br /> Hyponatraemia<br />Hyponatraemia may occur as a result of treatment with SSRIs or<br />SNRIs including Sertraline. In many cases, hyponatraemia appears to<br />be the result of a syndrome of inappropriate antidiuretic hormone<br />secretion (SIADH). Cases of serum sodium levels lower than 110<br />mmol/l have been reported.<br />Elderly patients may be at greater risk of developing hyponatraemia<br />with SSRIs and SNRIs. Also patients taking diuretics or who are<br />otherwise volume-depleted may be at greater risk (see Use in elderly).<br />Discontinuation of Sertraline should be considered in patients with<br />symptomatic hyponatraemia and appropriate medical intervention<br />should be instituted. Signs and symptoms of hyponatraemia include<br />headache, difficulty concentrating, memory impairment, confusion,<br />weakness and unsteadiness which may lead to falls. Signs and<br />symptoms associated with more severe and/or acute cases have<br />included hallucination, syncope, seizure, coma, respiratory arrest, and<br />death.<br /> Withdrawal symptoms seen on discontinuation of Sertraline<br />treatment<br />Withdrawal symptoms when treatment is discontinued are common,<br />particularly if discontinuation is abrupt (see section 4.8). In clinical<br />trials, among patients treated with Sertraline, the incidence of reported<br />withdrawal reactions was 23% in those discontinuing Sertraline<br />compared to 12% in those who continued to receive Sertraline<br />treatment.<br />The risk of withdrawal symptoms may be dependent on several factors<br />including the duration and dose of therapy and the rate of dose<br />reduction. Dizziness, sensory disturbances (including paraesthesia),<br />sleep disturbances (including insomnia and intense dreams), agitation<br />or anxiety, nausea and/or vomiting, tremor and headache are the most<br />commonly reported reactions. Generally these symptoms are mild to<br />moderate; however, in some patients they may be severe in intensity.<br />They usually occur within the first few days of discontinuing<br />treatment, but there have been very rare reports of such symptoms in<br />patients who have inadvertently missed a dose. Generally these<br />symptoms are self-limiting and usually resolve within 2 weeks, though<br />in some individuals they may be prolonged (2-3 months or more). It is<br />therefore advised that Sertraline should be gradually tapered when<br />SPC SETRAL 50 mg Film Coated Tablets<br />discontinuing treatment over a period of several weeks or months,<br />according to the patient&#39;s needs (see section 4.2).<br /> Akathisia/psychomotor restlessness<br />The use of Sertraline has been associated with the development of<br />akathisia, characterised by a subjectively unpleasant or distressing<br />restlessness and need to move often accompanied by an inability to sit<br />or stand still. This is most likely to occur within the first few weeks of<br />treatment. In patients who develop these symptoms, increasing the<br />dose may be detrimental.<br /> Hepatic impairment<br />Sertraline is extensively metabolised by the liver. A multiple dose<br />pharmacokinetic study in subjects with mild, stable cirrhosis<br />demonstrated a prolonged elimination half life and approximately<br />three-fold greater AUC and Cmax in comparison to normal subjects.<br />There were no significant differences in plasma protein binding<br />observed between the two groups. The use of Sertraline in patients<br />with hepatic disease must be approached with caution. If Sertraline is<br />administered to patients with hepatic impairment, a lower or less<br />frequent dose should be considered. Sertraline should not be used in<br />patients with severe hepatic impairment (see section 4.2).<br /> Renal impairment<br />Sertraline is extensively metabolised, and excretion of unchanged drug<br />in urine is a minor route of elimination. In studies of patients with mild<br />to moderate renal impairment (creatinine clearance 30-60 ml/min) or<br />moderate to severe renal impairment (creatinine clearance 10-29<br />ml/min), multiple-dose pharmacokinetic parameters (AUC0-24 or<br />Cmax) were not significantly different compared with controls.<br />Sertraline dosing does not have to be adjusted based on the degree of<br />renal impairment.<br /> Use in elderly<br />Over 700 elderly patients (&gt;65 years) have participated in clinical<br />studies. The pattern and incidence of adverse reactions in the elderly<br />was similar to that in younger patients.<br />SSRIs or SNRIs including Sertraline have however been associated<br />with cases of clinically significant hyponatraemia in elderly patients,<br />who may be at greater risk for this adverse event (see Hyponatraemia<br />in section 4.4).<br />SPC SETRAL 50 mg Film Coated Tablets<br /> Diabetes<br />In patients with diabetes, treatment with an SSRI may alter glycaemic<br />control. Insulin and/or oral hypoglycaemic dosage may need to be<br />adjusted.<br /> Electroconvulsive therapy<br />There are no clinical studies establishing the risks or benefits of the<br />combined use of ECT and Sertraline.<br /> Grapefruit juice<br />The administration of Sertraline with grapefruit juice is not<br />recommended (see section 4.5).<br /> Interference with urine screening tests<br />False-positive urine immunoassay screening tests for benzodiazepines<br />have been reported in patients taking Sertraline. This is due to lack of<br />specificity of the screening tests. False-positive test results may be<br />expected for several days following discontinuation of Sertraline<br />therapy. Confirmatory tests, such as gas chromatography/mass<br />spectrometry, will distinguish Sertraline from benzodiazepines.<br /> Angle-Closure Glaucoma<br />SSRIs including Sertraline may have an effect on pupil size resulting in<br />mydriasis. This mydriatic effect has the potential to narrow the eye<br />angle resulting in increased intraocular pressure and angle-closure<br />glaucoma, especially in patients pre-disposed. Sertraline should<br />therefore be used with caution in patients with angle-closure glaucoma<br />or history of glaucoma.<br />- SSRIs/ SNRIs may increase the risk of postpartum hemorrhage.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Contraindicated<br />Monoamine Oxidase Inhibitors<br />Irreversible MAOIs (e.g. selegiline)<br />Sertraline must not be used in combination with irreversible MAOIs<br />such as selegiline. Sertraline must not be initiated for at least 14 days<br />after discontinuation of treatment with an irreversible MAOI.<br />Sertraline must be discontinued for at least 7 days before starting<br />treatment with an irreversible MAOI (see section 4.3).<br />Reversible, selective MAO-A inhibitor (moclobemide)<br />SPC SETRAL 50 mg Film Coated Tablets<br />Due to the risk of serotonin syndrome, the combination of Sertraline<br />with a reversible and selective MAOI, such as moclobemide, should<br />not be given. Following treatment with a reversible MAO-inhibitor, a<br />shorter withdrawal period than 14 days may be used before initiation of<br />Sertraline treatment. It is recommended that Sertraline should be<br />discontinued for at least 7 days before starting treatment with a<br />reversible MAOI (see section 4.3).<br />Reversible, non-selective MAOI (linezolid)<br />The antibiotic linezolid is a weak reversible and non-selective MAOI<br />and should not be given to patients treated with Sertraline (see section<br />4.3).<br />Severe adverse reactions have been reported in patients who have<br />recently been discontinued from an MAOI (e.g. methylene blue) and<br />started on Sertraline or have recently had Sertraline therapy<br />discontinued prior to initiation of an MAOI. These reactions have<br />included tremor, myoclonus, diaphoresis, nausea, vomiting, flushing,<br />dizziness, and hyperthermia with features resembling neuroleptic<br />malignant syndrome, seizures, and death.<br />Pimozide<br />Increased pimozide levels of approximately 35% have been<br />demonstrated in a study of a single low dose pimozide (2 mg). These<br />increased levels were not associated with any changes in EKG. While<br />the mechanism of this interaction is unknown, due to the narrow<br />therapeutic index of pimozide, concomitant administration of<br />Sertraline and pimozide is contraindicated (see section 4.3).<br />Co-administration with Sertraline is not recommended<br />CNS depressants and alcohol<br />The co-administration of Sertraline 200 mg daily did not potentiate the<br />effects of alcohol, carbamazepine, haloperidol, or phenytoin on<br />cognitive and psychomotor performance in healthy subjects; however,<br />the concomitant use of Sertraline and alcohol is not recommended.<br />Other serotonergic drugs<br />See section 4.4.<br />Caution is also advised with fentanyl (used in general anaesthesia or in<br />the treatment of chronic pain), other serotonergic drugs (including<br />other serotonergic antidepressants, amphetamines, triptans), and with<br />other opiate drugs.<br />Special Precautions<br />Drugs that Prolong the QT Interval<br />SPC SETRAL 50 mg Film Coated Tablets<br />The risk of QTc prolongation and/or ventricular arrhythmias (e.g. TdP)<br />may be increased with concomitant use of other drugs which prolong the<br />QTc interval (e.g. some antipsychotics and antibiotics) (see section 4.4).<br />Lithium<br />In a placebo-controlled trial in normal volunteers, the coadministration<br />of Sertraline with lithium did not significantly alter<br />lithium pharmacokinetics, but did result in an increase in tremor<br />relative to placebo, indicating a possible pharmacodynamic interaction.<br />When co-administering Sertraline with lithium, patients should be<br />appropriately monitored.<br />Phenytoin<br />A placebo-controlled trial in normal volunteers suggests that chronic<br />administration of Sertraline 200 mg/day does not produce clinically<br />important inhibition of phenytoin metabolism. Nonetheless, as some<br />case reports have emerged of high phenytoin exposure in patients using<br />Sertraline, it is recommended that plasma phenytoin concentrations be<br />monitored following initiation of Sertraline therapy, with appropriate<br />adjustments to the phenytoin dose. In addition, co-administration of<br />phenytoin may cause a reduction of Sertraline plasma levels. It cannot<br />be excluded that other CYP3A4 inducers, e.g. phenobarbital,<br />carbamazepine, St John&#39;s Wort, rifampicin may cause a reduction of<br />Sertraline plasma levels.<br />Triptans<br />There have been rare post-marketing reports describing patients with<br />weakness, hyperreflexia, incoordination, confusion, anxiety and<br />agitation following the use of Sertraline and sumatriptan. Symptoms of<br />serotonergic syndrome may also occur with other products of the same<br />class (triptans). If concomitant treatment with Sertraline and triptans is<br />clinically warranted, appropriate observation of the patient is advised<br />(see section 4.4).<br />Warfarin<br />Co-administration of Sertraline 200 mg daily with warfarin resulted in<br />a small but statistically significant increase in prothrombin time, which<br />may in some rare cases unbalance the INR value.<br />Accordingly, prothrombin time should be carefully monitored when<br />Sertraline therapy is initiated or stopped.<br />Other drug interactions, digoxin, atenolol, cimetidine<br />SPC SETRAL 50 mg Film Coated Tablets<br />Co-administration with cimetidine caused a substantial decrease in<br />Sertraline clearance. The clinical significance of these changes is<br />unknown. Sertraline had no effect on the beta-adrenergic blocking<br />ability of atenolol. No interaction of Sertraline 200 mg daily was<br />observed with digoxin.<br />Drugs affecting platelet function<br />The risk of bleeding may be increased when medicines acting on<br />platelet function (e.g. NSAIDs, acetylsalicylic acid and ticlopidine) or<br />other medicines that might increase bleeding risk are concomitantly<br />administered with SSRIs, including Sertraline (see section 4.4).<br />Neuromuscular Blockers<br />SSRIs may reduce plasma cholinesterase activity resulting in a<br />prolongation of the neuromuscular blocking action of mivacurium or<br />other neuromuscular blockers.<br />Drugs Metabolized by Cytochrome P450<br />Sertraline may act as a mild-moderate inhibitor of CYP 2D6. Chronic<br />dosing with Sertraline 50 mg daily showed moderate elevation (mean<br />23%-37%) of steady-state desipramine plasma levels (a marker of CYP<br />2D6 isozyme activity). Clinical relevant interactions may occur with<br />other CYP 2D6 substrates with a narrow therapeutic index like class<br />1C antiarrhythmics such as propafenone and flecainide, TCAs and<br />typical antipsychotics, especially at higher Sertraline dose levels.<br />Sertraline does not act as an inhibitor of CYP 3A4, CYP 2C9, CYP<br />2C19, and CYP 1A2 to a clinically significant degree. This has been<br />confirmed by in-vivo interaction studies with CYP3A4 substrates<br />(endogenous cortisol, carbamazepine, terfenadine, alprazolam),<br />CYP2C19 substrate diazepam, and CYP2C9 substrates tolbutamide,<br />glibenclamide and phenytoin. In vitro studies indicate that Sertraline<br />has little or no potential to inhibit CYP 1A2.<br />Intake of three glasses of grapefruit juice daily increased the Sertraline<br />plasma levels by approximately 100% in a cross-over study in eight<br />Japanese healthy subjects. Therefore, the intake of grapefruit juice<br />should be avoided during treatment with Sertraline (see section 4.4).<br />Based on the interaction study with grapefruit juice, it cannot be<br />excluded that the concomitant administration of Sertraline and potent<br />CYP3A4 inhibitors, e.g. protease inhibitors, ketoconazole,<br />itraconazole, posaconazole, voriconazole, clarithromycin,<br />telithromycin and nefazodone, would result in even larger increases in<br />exposure of Sertraline. This also concerns moderate CYP3A4<br />inhibitors, e.g. aprepitant, erythromycin, fluconazole, verapamil and<br />diltiazem. The intake of potent CYP3A4 inhibitors should be avoided<br />during treatment with Sertraline.<br />SPC SETRAL 50 mg Film Coated Tablets<br />Sertraline plasma levels are enhanced by about 50% in poor<br />metabolizers of CYP2C19 compared to rapid metabolizers (see section<br />5.2). Interaction with strong inhibitors of CYP2C19, e.g. omeprazole,<br />lansoprazole, pantoprazole, rabeprazole, fluoxetine, fluvoxamine<br />cannot be excluded</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There are no well controlled studies in pregnant women. However, a<br />substantial amount of data did not reveal evidence of induction of<br />congenital malformations by Sertraline. Animal studies showed evidence<br />for effects on reproduction probably due to maternal toxicity caused by<br />the pharmacodynamic action of the compound and/or direct<br />pharmacodynamic action of the compound on the foetus (see 5.3).<br />Use of Sertraline during pregnancy has been reported to cause<br />symptoms, compatible with withdrawal reactions, in some neonates,<br />whose mothers had been on Sertraline. This phenomenon has also been<br />observed with other SSRI antidepressants. Sertraline is not recommended<br />in pregnancy, unless the clinical condition of the woman is such that the<br />benefit of the treatment is expected to outweigh the potential risk.<br />Neonates should be observed if maternal use of Sertraline continues into<br />the later stages of pregnancy, particularly the third trimester. The<br />following symptoms may occur in the neonate after maternal Sertraline<br />use in later stages of pregnancy: respiratory distress, cyanosis, apnoea,<br />seizures, temperature instability, feeding difficulty, vomiting,<br />hypoglycaemia, hypertonia, hypotonia, hyperreflexia, tremor, jitteriness,<br />irritability, lethargy, constant crying, somnolence and difficulty in<br />sleeping. These symptoms could be due to either serotonergic effects or<br />withdrawal symptoms. In a majority of instances the complications begin<br />immediately or soon (&lt;24 hours) after delivery.<br />Epidemiological data have suggested that the use of SSRIs in pregnancy,<br />particular in late pregnancy, may increase the risk of persistent<br />pulmonary hypertension in the newborn (PPHN). The observed risk was<br />approximately 5 cases per 1000 pregnancies. In the general population 1<br />to 2 cases of PPHN per 1000 pregnancies occur.<br />Breast-feeding<br />Published data concerning Sertraline levels in breast milk show that<br />small quantities of Sertraline and its metabolite N-desmethylSertraline<br />are excreted in milk. Generally negligible to undetectable levels were<br />found in infant serum, with one exception of an infant with serum levels<br />about 50% of the maternal level (but without a noticeable health effect in<br />this infant). To date, no adverse effects on the health of infants nursed by<br />mothers using Sertraline have been reported, but a risk cannot be<br />excluded. Use in nursing mothers is not recommended unless, in the<br />judgment of the physician, the benefit outweighs the risk.<br />Fertility<br />SPC SETRAL 50 mg Film Coated Tablets<br />Animal data did not show an effect of Sertraline on fertility parameters<br />(see section 5.3.).<br />Human case reports with some SSRI&#39;s have shown that an effect on<br />sperm quality is reversible.<br />Impact on human fertility has not been observed so far.<br />- observational data indicate an increased risk (less than 2- fold) of<br />postpartum haemorrhage following SSRI/ SNRI exposure within the<br />month prior to birth.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical pharmacology studies have shown that Sertraline has no effect<br />on psychomotor performance. However, as psychotropic drugs may<br />impair the mental or physical abilities required for the performance of<br />potentially hazardous tasks such as driving a car or operating machinery,<br />the patient should be cautioned accordingly.<br />4-8</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nausea is the most common undesirable effect. In the treatment of social<br />anxiety disorder, sexual dysfunction (ejaculation failure) in men occurred<br />in 14% for Sertraline vs 0% in placebo. These undesirable effects are<br />dose dependent and are often transient in nature with continued<br />treatment.<br />The undesirable effects profile commonly observed in double-blind,<br />placebo-controlled studies in patients with OCD, panic disorder, PTSD<br />and social anxiety disorder was similar to that observed in clinical trials<br />in patients with depression.<br />Table 1 displays adverse reactions observed from postmarketing<br />experience (frequency not known) and placebo-controlled clinical trials<br />(comprising a total of 2542 patients on Sertraline and 2145 on placebo)<br />in depression, OCD, panic disorder, PTSD and social anxiety disorder.<br />Some adverse drug reactions listed in Table 1 may decrease in intensity<br />and frequency with continued treatment and do not generally lead to<br />cessation of therapy.<br />Table 1: Adverse Reactions<br />Frequency of adverse reactions observed from placebo-controlled<br />clinical trials in depression, OCD, panic disorder, PTSD and social<br />anxiety disorder. Pooled analysis and postmarketing experience.<br />Table 1: Adverse Reactions<br />Frequency of adverse reactions observed from placebo-controlled clinical trials in depression, OCD, panic disorder,<br />PTSD and social anxiety disorder. Pooled analysis and post-marketing experience.<br />System Organ<br />Class<br />Very Common<br />(&ge;1/10)<br />Common<br />(&ge;1/100 to &lt;1/10)<br />Uncommon<br />(&ge;1/1,000 to<br />&lt;1/100)<br />Rare<br />(&ge;1/10,000 to &lt;1/1,000)<br />Frequency<br />Not Known<br />(Cannot be<br />Estimated<br />From the<br />Available<br />SPC SETRAL 50 mg Film Coated Tablets<br />Data)<br />Infections and<br />infestations<br />upper respiratory<br />tract<br />infection, pharyngitis,<br />rhinitis<br />gastroenteritis, otitis<br />media<br />diverticulitis&sect;<br />Neoplasms<br />benign, malignant<br />and unspecified<br />(including cysts<br />and polyps)<br />neoplasm<br />Blood and<br />lymphatic system<br />disorders<br />lymphadenopathy,<br />thrombocytopenia&lowast;&sect;,<br />leukopenia&lowast;&sect;<br />Immune system<br />disorders<br />hypersensitivity&lowast;,<br />seasonal allergy&lowast;<br />anaphylactoid reaction&lowast;<br />Endocrine<br />disorders<br />hypothyroidism&lowast; hyperprolactinaemia&lowast;&sect;,<br />inappropriate antidiuretic<br />hormone secretion&lowast;&sect;<br />Metabolism and<br />nutrition disorders<br />decreased appetite,<br />increased appetite&lowast;<br />hypercholesterolaemia,<br />diabetes mellitus&lowast;,<br />hypoglycaemia&lowast;,<br />hyperglycaemia&lowast;&sect;,<br />hyponatraemia&lowast;&sect;<br />Psychiatric<br />disorders<br />insomnia anxiety*, depression*,<br />agitation*,<br />libido decreased*,<br />nervousness,<br />depersonalisation,<br />nightmare, bruxism*<br />suicidal<br />ideation/behaviour,<br />psychotic disorder&lowast;,<br />thinking abnormal,<br />apathy,<br />hallucination*,<br />aggression*,<br />euphoric mood*,<br />paranoia<br />conversion disorder&lowast;&sect;,<br />paroniria&lowast;&sect;, drug<br />dependence, sleep<br />walking, premature<br />ejaculation<br />Nervous system<br />disorders<br />dizziness,<br />headache*, somnolence<br />tremor, movement<br />disorders (including<br />extrapyramidal<br />symptoms such as<br />hyperkinesia,<br />hypertonia, dystonia,<br />teeth grinding or gait<br />abnormalities),<br />paraesthesia*,<br />hypertonia*,<br />disturbance in<br />attention, dysgeusia<br />amnesia,<br />hypoaesthesia*,<br />muscle contractions<br />involuntary*,<br />syncope*,<br />hyperkinesia*,<br />migraine*,<br />convulsion*,<br />dizziness postural,<br />coordination<br />abnormal, speech<br />disorder<br />coma*, akathisia (see<br />section 4.4), dyskinesia,<br />hyperaesthesia,<br />cerebrovascular spasm<br />(including reversible<br />cerebral vasoconstriction<br />syndrome and Call-<br />Fleming syndrome)&lowast;&sect;,<br />psychomotor<br />restlessness&lowast;&sect; (see section<br />4.4), sensory<br />disturbance,<br />choreoathetosis&sect;, also<br />reported were signs and<br />symptoms associated<br />with serotonin<br />syndrome&lowast; or neuroleptic<br />malignant syndrome: In<br />some cases associated<br />with concomitant use of<br />serotonergic drugs that<br />included agitation,<br />confusion, diaphoresis,<br />diarrhoea, fever,<br />hypertension, rigidity<br />and tachycardia&sect;<br />SPC SETRAL 50 mg Film Coated Tablets<br />Eye disorders visual disturbance&lowast; mydriasis&lowast; scotoma, glaucoma,<br />diplopia, photophobia,<br />hyphaema&lowast;&sect;, pupils<br />unequal&lowast;&sect;, vision<br />abnormal&sect;, lacrimal<br />disorder<br />maculopathy<br />Ear and labyrinth<br />disorders<br />tinnitus&lowast; ear pain<br />Cardiac disorders palpitations&lowast; tachycardia&lowast;, cardiac<br />disorder<br />myocardial infarction&lowast;&sect;,<br />Torsade de Pointes&lowast;&sect; (see<br />sections 4.4, 4.5 and<br />5.1), bradycardia, QTc<br />prolongation&lowast;(see<br />sections 4.4, 4.5 and 5.1)<br />Vascular disorders hot flush&lowast; abnormal bleeding<br />(such as<br />gastrointestinal<br />bleeding)&lowast;,<br />hypertension&lowast;,<br />flushing,<br />haematuria&lowast;<br />peripheral ischaemia<br />Respiratory,<br />thoracic and<br />mediastinal<br />disorders<br />yawning&lowast; dyspnoea,<br />epistaxis&lowast;,<br />bronchospasm*<br />hyperventilation,<br />interstitial lung disease&lowast;&sect;,<br />laryngospasm,<br />dysphonia, stridor&lowast;&sect;,<br />hypoventilation, hiccups<br />Gastrointestinal<br />disorders<br />nausea, diarrhoea, dry<br />mouth<br />dyspepsia,<br />constipation*,<br />abdominal pain*,<br />vomiting*, flatulence<br />melaena, tooth<br />disorder,<br />oesophagitis,<br />glossitis,<br />haemorrhoids,<br />salivary<br />hypersecretion,<br />dysphagia,<br />eructation, tongue<br />disorder<br />mouth ulceration,<br />pancreatitis&lowast;&sect;,<br />haematochezia, tongue<br />ulceration, stomatitis<br />Microscopic<br />colitis<br />Hepatobiliary<br />disorders<br />hepatic function<br />abnormal, serious liver<br />events (including<br />hepatitis, jaundice and<br />hepatic failure)<br />Skin and<br />subcutaneous<br />tissue disorders<br />hyperhidrosis, rash* periorbital oedema*,<br />urticaria*, alopecia*,<br />pruritus*, purpura*,<br />dermatitis, dry skin,<br />face oedema, cold<br />sweat<br />rare reports of severe<br />cutaneous adverse<br />reactions (SCAR): e.g.<br />Stevens-Johnson<br />syndrome&lowast; and epidermal<br />necrolysis&lowast;&sect;, skin<br />reaction&lowast;&sect;,<br />photosensitivity&sect;,<br />angioedema, hair texture<br />abnormal, skin odour<br />abnormal, dermatitis<br />bullous, rash follicular<br />Musculoskeletal<br />and connective<br />tissue disorders<br />back pain, arthralgia&lowast;,<br />myalgia<br />osteoarthritis,<br />muscle twitching,<br />muscle cramps&lowast;,<br />muscular weakness<br />rhabdomyolysis&lowast;&sect;, bone<br />disorder<br />trismus*<br />Renal and urinary pollakiuria, urinary hesitation*,<br />SPC SETRAL 50 mg Film Coated Tablets<br />disorders micturition disorder,<br />urinary retention,<br />urinary<br />incontinence*,<br />polyuria, nocturia<br />oliguria<br />Reproductive<br />system and breast<br />disorders<br />ejaculation failure menstruation<br />irregular&lowast;, erectile<br />dysfunction<br />sexual dysfunction<br />(see section 4.4),<br />menorrhagia,<br />vaginal<br />haemorrhage,<br />female sexual<br />dysfunction (see<br />section 4.4)<br />galactorrhoea*, atrophic<br />vulvovaginitis, genital<br />discharge,<br />balanoposthitis&lowast;&sect;,<br />gynaecomastia&lowast;,<br />priapism*<br />Postpartum<br />hemorrhage *<br />General disorders<br />and administration<br />site conditions<br />fatigue* malaise*, chest pain*,<br />asthenia&lowast;, pyrexia&lowast;<br />oedema peripheral*,<br />chills, gait<br />disturbance&lowast;, thirst<br />hernia, drug tolerance<br />decreased<br />Investigations weight increased&lowast; alanine<br />aminotransferase<br />increased*, aspartate<br />aminotransferase<br />increased*, weight<br />decreased*<br />blood cholesterol<br />increased&lowast;, abnormal<br />clinical laboratory<br />results, semen abnormal,<br />altered platelet function&lowast;&sect;<br />Injury, poisoning<br />and procedural<br />complications<br />injury<br />Surgical and<br />medical<br />procedures<br />vasodilation procedure<br />&lowast; ADR identified post-marketing<br />&sect; ADR frequency represented by the estimated upper limit of the 95% confidence interval using &ldquo;The Rule of 3&rdquo;.<br />* this event has been reported for the therapeutic class of SSRIs/ SNRIs.<br />Withdrawal symptoms seen on discontinuation of Sertraline treatment<br />Discontinuation of Sertraline (particularly when abrupt) commonly leads<br />to withdrawal symptoms. Dizziness, sensory disturbances (including<br />paraesthesia), sleep disturbances (including insomnia and intense<br />dreams), agitation or anxiety, nausea and/or vomiting, tremor and<br />headache are the most commonly reported. Generally these events are<br />mild to moderate and are self-limiting; however, in some patients they<br />may be severe and/or prolonged. It is therefore advised that when<br />Sertraline treatment is no longer required, gradual discontinuation by<br />dose tapering should be carried out (see sections 4.2 and 4.4).<br />Elderly population<br />SSRIs or SNRIs including Sertraline have been associated with cases of<br />clinically significant hyponatraemia in elderly patients, who may be at<br />greater risk for this adverse event (see section 4.4).<br />Paediatric population<br />In over 600 paediatric patients treated with Sertraline, the overall profile<br />of adverse reactions was generally similar to that seen in adult studies.<br />The following adverse reactions were reported from controlled trials<br />(n=281 patients treated with Sertraline):<br />SPC SETRAL 50 mg Film Coated Tablets<br />Very common (&ge;1/10): Headache (22%), insomnia (21%), diarrhoea<br />(11%) and nausea (15%).<br />Common (&ge;1/100 to &lt;1/10): Chest pain, mania, pyrexia, vomiting,<br />anorexia, affect lability, aggression, agitation, nervousness, disturbance<br />in attention, dizziness, hyperkinesia, migraine, somnolence, tremor,<br />visual disturbance, dry mouth, dyspepsia, nightmare, fatigue, urinary<br />incontinence, rash, acne, epistaxis, flatulence.<br />Uncommon (&ge;1/1000 to &lt;1/100): ECG QT prolonged, suicide attempt,<br />convulsion, extrapyramidal disorder, paraesthesia, depression,<br />hallucination, purpura, hyperventilation, anaemia, hepatic function<br />abnormal, alanine aminotransferase increased, cystitis, herpes simplex,<br />otitis externa, ear pain, eye pain, mydriasis, malaise, haematuria, rash<br />pustular, rhinitis, injury, weight decreased, muscle twitching, abnormal<br />dreams, apathy, albuminuria, pollakiuria, polyuria, breast pain, menstrual<br />disorder, alopecia, dermatitis, skin disorder, skin odour abnormal,<br />urticaria, bruxism, flushing.<br />Frequency not known: enuresis<br />Class effects<br />Epidemiological studies, mainly conducted in patients 50 years of age<br />and older, show an increased risk of bone fractures in patients receiving<br />SSRIs and TCAs. The mechanism leading to this risk is unknown.<br />Saudi Arabia: To report any side effect(s): National Pharmacovigilance Center<br />(NPC): Fax: +966-11-205-7662, SFDA Call center: 19999, E-mail:<br />npc.drug@sfda.gov.sa, Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Toxicity<br />Sertraline has a margin of safety dependent on patient population and/or<br />concomitant medication. Deaths have been reported involving overdoses<br />of Sertraline, alone or in combination with other drugs and/or alcohol.<br />Therefore, any overdosage should be medically treated aggressively.<br />Symptoms<br />Symptoms of overdose include serotonin-mediated side effects such as<br />somnolence, gastrointestinal disturbances (such as nausea and vomiting),<br />tachycardia, tremor, agitation and dizziness. Coma has been reported<br />although less frequently.<br />QTc prolongation/Torsade de Pointes has been reported following<br />sertraline overdose; therefore, ECG-monitoring is recommended in all<br />ingestions of sertraline overdoses.<br />Managment<br />There are no specific antidotes to Sertraline. It is recommended to<br />establish and maintain an airway and, if necessary, ensure adequate<br />oxygenation and ventilation. Activated charcoal, which may be used with<br />a cathartic, may be as, or more effective than lavage, and should be<br />SPC SETRAL 50 mg Film Coated Tablets<br />considered in treating overdose. Induction of emesis is not<br />recommended. Cardiac (e.g. ECG) and vital sign monitoring is also<br />recommended, along with general symptomatic and supportive measures.<br />Due to the large volume of distribution of sertraline, forced diuresis,<br />dialysis, haemoperfusion and exchange transfusion are unlikely to be of<br />benefit</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Selective serotonin reuptake inhibitors<br />(SSRI)<br />ATC Code: N06 AB06<br />Mechanism of action<br />Sertraline is a potent and specific inhibitor of neuronal serotonin (5 HT)<br />uptake in vitro, which results in the potentiation of the effects of 5-HT in<br />animals. It has only very weak effects on norepinephrine and dopamine<br />neuronal reuptake. At clinical doses, Sertraline blocks the uptake of<br />serotonin into human platelets. It is devoid of stimulant, sedative or<br />anticholinergic activity or cardiotoxicity in animals. In controlled studies<br />in normal volunteers, Sertraline did not cause sedation and did not<br />interfere with psychomotor performance. In accord with its selective<br />inhibition of 5-HT uptake, Sertraline does not enhance catecholaminergic<br />activity. Sertraline has no affinity for muscarinic (cholinergic),<br />serotonergic, dopaminergic, adrenergic, histaminergic, GABA or<br />benzodiazepine receptors. The chronic administration of Sertraline in<br />animals was associated with down-regulation of brain norepinephrine<br />receptors as observed with other clinically effective antidepressants and<br />antiobsessional drugs.<br />Sertraline has not demonstrated potential for abuse. In a placebocontrolled,<br />double-blind randomized study of the comparative abuse<br />liability of Sertraline, alprazolam and d-amphetamine in humans,<br />Sertraline did not produce positive subjective effects indicative of abuse<br />potential. In contrast, subjects rated both alprazolam and d-amphetamine<br />significantly greater than placebo on measures of drug liking, euphoria<br />and abuse potential. Sertraline did not produce either the stimulation and<br />anxiety associated with d-amphetamine or the sedation and psychomotor<br />impairment associated with alprazolam. Sertraline does not function as a<br />positive reinforcer in rhesus monkeys trained to self administer cocaine,<br />nor does it substitute as a discriminative stimulus for either damphetamine<br />or pentobarbital in rhesus monkeys.<br />Clinical efficacy and safety<br />Major Depressive Disorder<br />A study was conducted which involved depressed outpatients who had<br />responded by the end of an initial 8-week open treatment phase on<br />Sertraline 50-200 mg/day. These patients (n=295) were randomized to<br />SPC SETRAL 50 mg Film Coated Tablets<br />continuation for 44 weeks on double-blind Sertraline 50-200 mg/day or<br />placebo. A statistically significantly lower relapse rate was observed for<br />patients taking Sertraline compared to those on placebo. The mean dose<br />for completers was 70 mg/day. The % of responders (defined as those<br />patients that did not relapse) for Sertraline and placebo arms were 83.4%<br />and 60.8%, respectively.<br />Post traumatic stress disorder (PTSD)<br />Combined data from the 3 studies of PTSD in the general population<br />found a lower response rate in males compared to females. In the two<br />positive general population trials, the male and female Sertraline vs.<br />placebo responder rates were similar (females: 57.2% vs 34.5%; males:<br />53.9% vs 38.2%). The number of male and female patients in the pooled<br />general population trials was 184 and 430, respectively and hence the<br />results in females are more robust and males were associated with other<br />baseline variables (more substance abuse, longer duration, source of<br />trauma etc) which are correlated with decreased effect.<br />Cardiac Electrophysiology<br />In a dedicated thorough QTc study, conducted at steady state at<br />supratherapeutic exposures in healthy volunteers (treated with 400<br />mg/day, twice the maximum recommended daily dose), the upper bound<br />of the 2-sided 90% CI for the time matched Least Square mean<br />difference of QTcF between sertraline and placebo (11.666 msec) was<br />greater than the predefined threshold of 10 msec at the 4-hour postdose<br />time point. Exposure-response analysis indicated a slightly positive<br />relationship between QTcF and sertraline plasma concentrations [0.036<br />msec/(ng/mL); p&lt;0.0001].<br />Based on the exposure response model, the threshold for clinically<br />significant prolongation of the QTcF (i.e. for predicted 90% CI to exceed<br />10 msec) is at least 2.6-fold greater than the average Cmax (86 ng/mL)<br />following the highest recommended dose of sertraline (200 mg/day) (see<br />sections 4.4, 4.5, 4.8 and 4.9).<br />Paediatric OCD<br />The safety and efficacy of Sertraline (50-200 mg/day) was examined in<br />the treatment of non-depressed children (6-12 years old) and adolescent<br />(13-17 years old) outpatients with obsessive compulsive disorder (OCD).<br />After a one week single blind placebo lead-in, patients were randomly<br />assigned to twelve weeks of flexible dose treatment with either Sertraline<br />or placebo. Children (6-12 years old) were initially started on a 25 mg<br />dose. Patients randomized to Sertraline showed significantly greater<br />improvement than those randomised to placebo on the Children&#39;s Yale-<br />Brown Obsessive Compulsive Scale CY-BOCS (p =0.005) the NIMH<br />Global Obsessive Compulsive Scale (p=0.019), and the CGI<br />Improvement (p =0.002) scales. In addition, a trend toward greater<br />improvement in the Sertraline group than the placebo group was also<br />observed on the CGI Severity scale (p=0.089). For CY-BOCs the mean<br />baseline and change from baseline scores for the placebo group was<br />22.25 &plusmn; 6.15 and -3.4 &plusmn; 0.82, respectively, while for the Sertraline group,<br />SPC SETRAL 50 mg Film Coated Tablets<br />the mean baseline and change from baseline scores were 23.36 &plusmn; 4.56<br />and -6.8 &plusmn; 0.87, respectively. In a post-hoc analysis, responders, defined<br />as patients with a 25% or greater decrease in the CY-BOCs (the primary<br />efficacy measure) from baseline to endpoint, were 53% of Sertralinetreated<br />patients compared to 37% of placebo-treated patients (p=0.03).<br />Long term safety and efficacy data are lacking for this paediatric<br />population.<br />Paediatric population<br />No data is available for children under 6 years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />In man, following an oral once-daily dosage of 50 to 200 mg for 14 days,<br />peak plasma concentrations of sertraline occur at 4.5 to 8.4 hours after the<br />daily administration of the drug. Food does not significantly change the<br />bioavailability of sertraline tablets.<br />Distribution<br />Approximately 98% of the circulating drug is bound to plasma proteins.<br />Biotransformation<br />Sertraline undergoes extensive first-pass hepatic metabolism.<br />Based on clinical and in-vitro data, it can be concluded that Sertraline is<br />metabolized by multiple pathways including CYP3A4, CYP2C19 (see<br />section 4.5) and CYP2B6. Sertraline and its major metabolite<br />desmethylSertraline are also substrate of P-glycoprotein in-vitro.<br />Elimination<br />The mean half-life of Sertraline is approximately 26 hours (range 22-36<br />hours). Consistent with the terminal elimination half-life, there is an<br />approximately two-fold accumulation up to steady state concentrations,<br />which are achieved after one week of once-daily dosing. The half-life of NdesmethylSertraline<br />is in the range of 62 to 104 hours. Sertraline and NdesmethylSertraline<br />are both extensively metabolized in man and the<br />resultant metabolites excreted in faeces and urine in equal amounts. Only a<br />small amount (&lt;0.2%) of unchanged Sertraline is excreted in the urine.<br />Linearity/non-linearity<br />Sertraline exhibits dose proportional pharmacokinetics in the range of 50 to<br />200 mg.<br />Pharmacokinetics in specific patient groups<br />Paediatric patients with OCD<br />SPC SETRAL 50 mg Film Coated Tablets<br />Pharmacokinetics of Sertraline was studied in 29 paediatric patients aged 6-<br />12 years old, and 32 adolescent patients aged 13-17 years old. Patients were<br />gradual uptitrated to a 200 mg daily dose within 32 days, either with 25 mg<br />starting dose and increment steps, or with 50 mg starting dose or<br />increments. The 25 mg regimen and the 50 mg regimen were equally<br />tolerated. In steady state for the 200 mg dose, the Sertraline plasma levels<br />in the 6-12 year old group were approximately 35% higher compared to the<br />13-17 year old group, and 21% higher compared to adult reference group.<br />There were no significant differences between boys and girls regarding<br />clearance. A low starting dose and titration steps of 25 mg are therefore<br />recommended for children, especially with low bodyweight. Adolescents<br />could be dosed like adults.<br />Adolescents and elderly<br />The pharmacokinetic profile in adolescents or elderly is not significantly<br />different from that in adults between 18 and 65 years.<br />Hepatic impairment<br />In patients with liver damage, the half life of Sertraline is prolonged and<br />AUC is increased three fold (see sections 4.2 and 4.4).<br />Renal impairment<br />In patients with moderate-severe renal impairment, there was no significant<br />accumulation of Sertraline.<br />Pharmacogenomics<br />Plasma levels of Sertraline were about 50% higher in poor metabolizers of<br />CYP2C19 versus extensive metabolizers. The clinical meaning is not clear,<br />and patients need to be titrated based on clinical response.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data does not indicate any special hazard for humans based on<br />conventional studies of safety pharmacology, repeated dose toxicity,<br />genotoxicity and carcinogenesis. Reproduction toxicity studies in animals<br />showed no evidence of teratogenicity or adverse effects on male fertility.<br />Observed foetotoxicity was probably related to maternal toxicity. Postnatal<br />pup survival and body weight were decreased only during the first days<br />after birth. Evidence was found that the early postnatal mortality was due to<br />in-utero exposure after day 15 of pregnancy. Postnatal developmental<br />delays found in pups from treated dams were probably due to effects on the<br />dams and therefore not relevant for human risk.<br />Juvenile animal studies<br />Animal data from rodents and non-rodents does not reveal effects on<br />fertility.<br />A juvenile toxicology study in rats has been conducted in which sertraline<br />was administered orally to male and female rats on Postnatal Days 21<br />through 56 (at doses of 10, 40, or 80 mg/kg/day) with a nondosing recovery<br />phase up to Postnatal Day 196. Delays in sexual maturation occurred in<br />SPC SETRAL 50 mg Film Coated Tablets<br />males and females at different dose levels (males at 80 mg/kg and females<br />at &ge;10 mg/kg), but despite this finding there were no sertraline-related<br />effects on any of the male or female reproductive endpoints that were<br />assessed. In addition, on Postnatal Days 21 to 56, dehydration,<br />chromorhinorrhea, and reduced average body weight gain was also<br />observed. All of the aforementioned effects attributed to the administration<br />of sertraline were reversed at some point during the nondosing recovery<br />phase of the study. The clinical relevance of these effects observed in rats<br />administered sertraline has not been established.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline Cellulose 50 micrometer<br /> Anhydrous Calcium Hydrogen Phosphate<br /> Sodium Starch Glycolate (Type A)<br /> Hydroxypropyl Cellulose (Klucel EF)<br /> Magnesium Stearate<br /> Hydroxypropyl Methylcellulose Type 2910 (Methocel E5)<br /> Polyethylene Glycol 400<br /> Titanium Dioxide<br /> White Beeswax</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SETRAL 50 Tablets should not be stored at a temperature above 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SETRAL 50 Tablets are packed in boxes of 10 Tablets blistered in<br />PVC/ aluminium foil.<br /> SETRAL 50 Tablets are packed in boxes of 30 Tablets blistered in<br />PVC/ aluminium foil.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Jordanian Pharmaceutical Manufacturing Co. Ltd.
PO Box 151
Um Al-Amad 16197
Jordan
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2020.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>